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Chair:  Dennis Keith Bishop 
  
Cardiac transplantation is an effective treatment for multiple types of heart failure 
refractive to therapy.  Although immunosuppressive therapeutics have increased survival 
rates within the first year post-transplant, chronic rejection (CR) remains a significant 
barrier to long term graft survival.  Indicators of CR include patchy interstitial fibrosis, 
vascular occlusion, and progressive loss of graft function.  However, the functional and 
anatomical changes associated with CR, as well as the factors responsible for the 
induction and progression of the disease are not understood.  These experiments utilized 
serial echocardiography to assess the progression of chronic rejection in vascularized 




that develop chronic rejection were compared with those receiving anti-CD40L therapy 
that do not develop chronic rejection.  Echocardiography revealed the development of 
hypertrophy in grafts undergoing chronic rejection which was confirmed by histologic 
analysis and coincided with graft fibrosis and elevated intragraft expression of IL-6.  To 
elucidate the role of IL-6 in chronic rejection, cardiac allograft recipients depleted of 
CD4+ cells were treated with neutralizing anti-IL-6 mAb.  IL-6 neutralization 
ameliorated cardiomyocyte hypertrophy, graft fibrosis, and prevented deterioration of 
graft contractility associated with chronic rejection.  The association of IL-6 with CR 
prompted us to investigate the relationship between IL-6 and two other factors known to 
be associated with CR, namely TGFβ and connective tissue growth factor (CTGF).  To 
this end, we utilized forced expression and neutralizing antibody approaches.  
Transduction of allografts with CTGF significantly increased fibrotic tissue development, 
though not to levels observed with TGFβ transduction.  Further, intragraft CTGF 
expression was inhibited by IL-6 neutralization while TGFβ expression remained 
unchanged, indicating that IL-6 effects may potentiate TGFβ-mediated induction of 
CTGF.  Finally, neutralizing CTGF significantly reduced graft fibrosis without reducing 
TGFβ and IL-6 expression levels.  These findings indicate that IL-6 and TGFβ function 
as promoters of CR while CTGF functions as a downstream mediator of fibrosis in CR.  





Chapter I—The Origins of Cardiac Transplantation 
 
 The concept of human heart transplantation may have been first described in the 
book of Liezi around 400 AD in China.  This tale describes how Bian Que exchanged the 
hearts of two warriors (1) with the chimerical aim of this legendary exchange being to 
balance the personal characteristics of both warriors.  Throughout history, the human 
fascination with the potential of joining favorable characteristics of different bodies, 
much like transplantation, extended to inter-specific grafting in ancient mythology where 
human forms were augmented by those of other animals (merfolk, centaurs, sphinx, etc.).  
Those ancient amalgams are now juxtaposed with the horrific, more recent literary 
descriptions of vampires, werewolves, and Shelly’s Frankenstein—a monster literally 
sewn together from the body parts of criminals.  In contrast, modern transplantation uses 
grafting as a therapeutic to combat disease.   
Beginnings of Transplant—Success and Failure 
The history of modern transplantion spans over one hundred years and includes 
several of the most significant discoveries in the study of immunology (Figure 1).  The 
origin of therapeutic organ transplantation traces back to the seminal work by Alexis 
Carrel and Charles Guthrie that overcame the first technical barrier to organ 
transplantation—suturing blood vessels.  Carrel and Guthrie’s experimental advances in 




organ transplant in which they describe the function of a dog kidney transplanted into the 
neck of another dog (2).  This was followed by the grafting of a puppy heart into the neck 
of a dog.  In this experiment, the donor heart resumed beating approximately one hour 
after the operation.  The grafted heart continued to beat for approximately two hours, at 
which point the experiment was interrupted due to blood coagulation in the cavities of the 
heart (3).  These and subsequent reports by Carrel marked the beginning of the science of 
organ transplantation (4). 
 
Figure 1 Timeline of Transplantation History 
During the years that Carrel and Guthrie pioneered their anastomosis technique 




performed his seminal work that laid the foundation for understanding the 
―biocompatibility‖ of human blood and tissues.  At that point in history blood transfusion 
was technically possible, though the results of transfusion were often deadly.  During his 
early career, Landsteiner performed numerous autopsies on patients who had become sick 
as a result of a blood transfusion or injection of foreign proteins (5).  The general tissue 
destruction and massive blood cell lysis seen in these patients intrigued Landsteiner to the 
point that he decided to pursue this problem rather than following his initial discovery of 
the polio virus in 1908 (6, 7).  In studying this problem, Landsteiner conjectured that 
genetic differences between humans could account for serum sickness (8).  The in vitro 
system that Landsteiner and colleagues developed led to the discovery of ABO blood 
groups and the very beginning of our understanding of biologic compatibility of 
transplanted tissues.  However, the importance of ABO matching donor grafts to their 
recipients was not fully appreciated at first (9). 
In 1912, George Shone summarized the growing understanding of transplant 
compatibility (10).  In his description he summarized what was known from earliest 
observations—that grafts between species always failed, that autografts (self grafts) 
mostly succeeded, and that allografts usually failed.  However, it was known that the 
likelihood of success for an allograft increased with closer familial relationship between 
donor and host.  Further, the speed with which a graft failed increased when an allograft 
recipient received subsequent allografts.  These observations of transplant failure would 




 The next significant progress in experimental heart transplantation was reported in 
1933 and built upon the canine heart transplantation work begun by Carrel and Guthrie.  
Though the initial work described orthotopic transplant of a dog heart that resumed 
function, the graft functioned for less than two hours.  Several important observations 
resulted from their findings; perhaps the most important being that a heart cut off from 
blood supply and moved into another recipient could resume function upon reperfusion 
with the recipient’s blood flow.  However given the short survival of the graft and that 
the transplant operation lasted several hours, the technique had immense room for 
improvement.  Toward this end Mann, Priestley,
 
Markowitz, and Yates spent 
considerable efforts improving the survival times of transplanted dog hearts to a mean of 
four hours, with one heart surviving for eight hours (11).  
 In 1945, R. D. Owen described red cell chimerism in dizygotic twin cattle.  This 
observation went largely unnoticed until Frank McFarlane Burnett revisited Owens 
observations in his famous 1949 writing introducing the idea of a basal state of tolerance, 
mediated by ―self molecules‖ (12).  By 1953, experiments by Sir Peter Medawar and 
colleagues demonstrated that it was possible to experimentally induce tolerance to 
antigens by introducing them to chick embryos and fetal mice.  Together, these 
experiments laid the foundation of our current understanding of transplant immunology, 
in light of ―acquired immunological tolerance‖ (13). 
 Public opinion was largely against organ transplantation in the 1950s, a time 
when most surgeons worked throughout the night in secret and the earliest cadaveric 




harvested from executed criminals, a practice that continues in some countries today (14).  
Negative perceptions of organ transplantation were solidified by consistently negative 
results.  In spite of great efforts at this time acute rejection was the rule, with organ 
failure within hours or days of the operation.  But then in 1954 a 23 year old patient 
named Richard Herrick was hospitalized for kidney disease (15).  As his condition 
deteriorated it became apparent that Richard would not survive without a functioning 
kidney.  However, unlike the many organ recipients before him, Richard had a healthy 
twin brother, Ronald, who wanted to donate a kidney to save his brother.  The brothers 
were referred to Joseph Murray at Peter Bent Brigham hospital, who was doing extensive 
experimental work at the time (16).  After 5 ½ hours of operating, both brothers were in 
recovery.  The transplant was successful and paved the way for many more successful 
identical twin transplants to come.  Further, the success of identical twin transplantation 
demonstrated the viability of organ transplantation as a therapeutic and made clear that 
―non-self‖ factors were the culprits responsible for transplant rejection.  Richard Herrick 
remained healthy for another 8 years, married, and had children before dying of kidney 
complications unrelated to the surgery while his brother Ronald was still living as of May 
2008 at 77 years of age (17).   
 One year later in 1955 Gordon Murray performed the first heart valve transplant 
(18).  This first transplant was followed by numerous others, each with improvement in 
aortic or mitral insufficiencies and showing remarkable short to mid-term durability.  
Though these transplants were successful, even at times crossing ABO compatibility 




questions were likely raised by the successes of such heart valve transplants, including 
why the transplant of a valve alone appeared to have less bioincompability compared to 
transplanting the whole organ.    
 Three years later, a major milestone in understanding the bioincompatibility of 
transplanted organs was achieved when Jean Dausset discovered the human leukocyte 
antigen (HLA)-A2, the first human major histocompatibility complex (MHC) molecule 
(20).  Soon after Dausset discovered HLA-A2, Jon J. Van Rood and colleagues reported 
anti-leukocyte antibodies detected in serum taken from pregnant women (21), supporting 
initial observations by Paul A. Gorer that mice could produce antibodies against H-2 
histocompatibility locus antigens (22).  Though these reports represented only the very 
beginning of our understanding of tissue matching science, these discoveries were the 
first glimpse that it might be possible to gain molecular knowledge of the endogenous 
factors or ―self molecules‖ that make some grafts more compatible with specific 
recipients and determine Medawar and Burnett’s ―acquired immunologic tolerance‖ (13).  
Advances in the understanding of tissue matching have greatly increased the potential for 
graft-recipient compatibility, though increased understanding of which HLA 
combinations are more and less immunogenic is still needed to better predict graft 
compatibility (23). 
Transplantation Research Gains Momentum 
In addition to studies that set the groundwork for defining challenges of graft 
acceptance by the immune system, the 1950s saw significant improvements in another 




experimental heart transplantations prior to this time had been heterotopic, or put outside 
of the position for the normal heart, while the native heart continued to bear the 
recipient’s circulatory burden.  However, the placement of heterotopic grafts outside the 
chest cavity impairs their ability to function as the primary circulatory organ.  The answer 
to this was the development of the orthotopic transplant technique, which was made 
possible in part through the advent of cardiopulmonary bypass by John H. Gibbon (3, 
24).  Though multiple groups had approached orthotopic transplantation throughout the 
50’s, the technique is generally attributed to the landmark report by Shumway and Lower 
in 1961 (25), which first outlined the theory and execution of the atrial cuff technique.  
This technique, unique in that it was post operatively fully capable of supporting the 
recipient’s circulatory system, allowed recipient dogs to resume normal exercise for 
weeks post transplant (3).  Shumway and Lower’s technique had far reaching 
implications for the future of cardiac transplantation, as the surgical techniques necessary 
for successful human heart transplantation were now in place.   
 It was also in the early 1960s that the first major breakthrough in treating 
immunologic rejection occurred.  As with orthotopic transplantation, the story of the first 
immunosuppressant began in the 1950’s, when Gertrude B. Elion and George H. Hitchins 
pioneered work in the use of ―antimetabolites‖, or chemicals that antagonize the bases 
that comprise nucleic acids (26).  By 1951, the research group had screened over 100 
mercaptopurines leading to the discovery of several promising candidates, including 6-
Mercaptopurine (6-MP).  6-MP demonstrated outstanding promise as a chemotherapeutic 




began screening variations of the drug made with chemical substitutions in hopes of 
finding an effective variant with diminished toxicity.  By 1958, Robert Schwartz began 
investigating the potential of 6-MP as an immunosuppressant, supposedly in part because 
the lymphocyte proliferation associated with acute leukemias appeared similar to that 
associated with transplant rejection (26).  Schwartz focused his studies on the ability of 6-
MP to alter antibody production.  Interestingly, Schwartz’s findings were that 6-MP 
needed to be administered concomitantly with antigen to prevent the production of 
antibody (27), and that administration of antigen after immunosuppression could actually 
augment antibody production (28).  However, the most important of Schwartz’s findings 
was undoubtedly several years later, when they reported that tolerance to antigen could 
be drug induced without ablating the capacity to respond to other antigens (29).   
The Beginning of Clinical Transplantation 
Schwartz’s findings with 6-MP sparked a series of investigations by Roy Calne, 
who in the early 1960’s employed first 6-MP then the more efficacious azathioprine (as 
suggested by Gertrude B. Elion) to prevent kidney rejection in dogs (30-32).  By 1962 
combination treatment of azathioprine with steroids had made survival of kidney 
homografts in man a reality (33).  Though there were still considerable side effects of the 
steroids administered with azathioprine, Calne’s research marks the dawn of 
immunosuppressive drug therapy to prevent graft rejection in man.  This seminal work 
ignited a surge of interest in organ transplantation as there was now a means to prevent 
immunologic rejection.  1963 saw the achievement of the first single human lung 




Thomas E. Starzl (35, 36).  These were certainly intrepid efforts, and though Hardy’s 
operation was surgically successful, these operations were performed on terminally ill 
patients and the outcomes could not be considered clinical successes.  However, such 
early failures clearly reiterated the need for greater understanding of transplant biology 
and paved the way for subsequent attempts at transplanting other organs.   
In 1964, a terminally ill patient who had suffered from years of chronic 
hypertension came under the care of Hardy and associates became the first human 
recipient of a heart transplant (37).  As no suitable human donor heart was available, they 
performed the xenotransplant of a heart from a chimpanzee that Hardy had brought back 
from a recent visit to another laboratory.  Upon warming and reperfusion, the 
transplanted heart resumed contraction for at least 90 minutes, however it was 
immediately apparent that the organ had insufficient contractile capacity to support the 
circulation of the large man (38).  The failure of this operation prompted an outcry of 
severe criticism from both the general public and the medical profession, as the United 
States populace was now embroiled in the ethical, moral, and legal quandary of heart 
transplantation (10).  The advent of heart transplantation detonated these issues for a very 
specific reason.  The harvesting of the donor organ in the United States was never 
performed before the donor underwent full cardiopulmonary arrest.  However harvesting 
organs after cardiopulmonary arrest is especially detrimental to hearts, which lose 
functional capacity and the ability to be resuscitated rapidly.  An additional barrier facing 
Hardy and others at the time was the intense increase of restrictions on clinical research 




significance of these stated or implied restrictions was attested by the fact that the second 
clinical heart transplantation was performed, not in the United States, where most of the 
developmental research in heart transplantation had been carried out, but in a foreign 
country, where support for laboratory research would appear to be somewhat limited‖ 
(39). 
The second clinical heart transplant to which Hardy referred was performed by 
the team led by Christiaan Barnard working at Groote Schuur Hospital in Cape Town, 
South Africa (40).  Louis Washkansky, the 54 year old recipient, received the heart of a 
young woman, Denise Darvell, killed in an automobile accident.  The surgical technique 
was adapted from the one introduced by Shumway, and Washkansky received a barrage 
of immunosuppressive treatments including intravenous hydrocortisone, oral prednisone, 
nasogastric azathioprine, local irradiation of the heart with Cobalt
60
, as well as 
actinomycin-C (10).  The graft appeared to function normally, however Washkansky 
succumbed to pneumonia 18 days later, perhaps a result of the intense 
immunosuppressive treatments.  Barnard’s group continued to perform heart transplants 
and two of the group’s first 10 transplant recipients lived for 13 and 23 years—long 
enough to raise global optimism of the viability of cardiac transplants as therapeutics in 
spite of widespread failures elsewhere (41).  Thus, in Cape Town, South Africa in 1967 
two streams of medical research merged; one had investigated the surgical techniques 
originating from Carrel and Guthrie while the other, which sought to understand 




In addition to the inception of clinical heart transplantation, the 1960s saw several 
significant breakthroughs in basic science related to transplant immunology.  Seminal 
work in tissue matching by Dausset and Van Rood was bolstered by the report of the 
microcytotoxicity test by Paul I. Terasaki (42).  The importance of this assay was not 
seen through immediate clinical relevance, but rather that it facilitated the classification 
of HLA antigens (43).  It was known at the time that the main compatibility necessary for 
initial transplant acceptance was to avoid crossing ABO blood compatibility boundaries, 
as this invariably induced hyperacute rejection, irrespective of the presence of 
immunotherapeutic treatment (44).  However, as Terasaki continued looking at host-
donor compatibility, he provided in 1965 a preliminary description of hyperacute 
rejection in a graft that did not cross ABO compatibility lines with the donor (43).  The 
critical observation in this case was that Terasaki was able to provide conclusive 
evidence that the manifestation of hyperacute rejection in this circumstance was 
precipitated by pre-formed anti-HLA antibodies in the recipient (45, 46).  This began the 
use of Terasaki’s crossmatch test. 
Another breakthrough occurred when scientists at Sandoz in Basel, who had been 
screening fungal metabolite compounds for antibiotic and anti-cancer effects, decided to 
tune their screening process to assay immunosuppressive agents as well.  This led to the 
discovery of Ciclosporin A (now Cyclosporine A or Sandimmune), a drug whose history 
is quite controversial (47-49).    Early experiments comparing Cyclosporine A to other 
cytostatic drugs showed that Cyclosporine A was ineffective in vitro but was able to exert 




unlike azathioprine, Cyclosporine A was much less effective at suppressing cytoxicity of 
an established immune response, indicating that known immunosuppressive drugs 
exhibited a divergence in their methods of action (50).  Further investigation revealed that 
unlike other cytostatic and immunosuppressants, Cyclosporine A had significantly lower 
myelotoxicity (51).  One of the first challenges of utilizing Cyclosporine A was that the 
compound is nearly insoluble in water.  However, it was soon discovered that the 
compound could be delivered dissolved in oil to patients (31).  The first use of 
Cyclosporine A in the clinic was to treat renal graft recipients, with exceptionally 
promising results—improving the first year post transplant survival rate from 50% (with 
azothioprine and steroids) to nearly 80% (52).  The great success of Cyclosporine A 
launched increased efforts to identify new immunosuppressive agents. 
 Advances in immunotherapeutics opened the door to increased number of 
transplants by providing a means with which to combat rejection.  However, 
immunosuppressive drug regimens caused significant side effects.  Hence, using a 
minimal amount of immunosuppression would clearly be beneficial for transplant 
recipients.  In order to effectively combat rejection with said minimal amount of 
immunosuppression, a means for both defining and monitoring graft rejection was needed 
in the clinic.  The answer to this problem came when Philip Caves introduced the 
transvenous endomyocardial biopsy.  Caves’ technique utilized a modified flexible 
bioptome that could be inserted into the internal jugular vein, continuing through the 
superior vena cava and right atrium through the tricuspid valve into the right ventricle for 




outpatient procedure in part because it only required local anesthesia and is repeatedly 
well tolerated—even as many as 30 times through the same vessel (54).  One of the 
primary debates over the use of biopsy for monitoring graft rejection is the question as to 
whether or not a biopsy can be assumed to represent the whole tissue.  For this reason at 
least 5 samples are taken from each biopsy performed to minimize the risk of 
misdiagnosis (55).  The use of transvenous endomyocardial biopsy had a major drawback 
in its nascent years—that a uniform grading system was lacking.  This problem was 
eventually addressed by the International Society of Heart and Lung Transplantation first 
in 1990 (56) and most recently in December of 2004 (57).  These two efforts have 
improved consistency in assessing rejection severity, though occurrences of endocardial 
infiltrates known as ―Quilty regions‖, humoral rejection, biopsy-negative rejection, and 
the possibility of regulatory T cell infiltrates (58) still obfuscate clear analysis of clinical 
samples (59, 60). 
 By 1983, a little over a decade after Jean Borel and colleagues discovered the 
immunosuppressive activity of Cyclosporine A, the United States Food and Drug 
Administration approved its use for the prevention of transplant rejection in patients and 
paved the way for more transplants than ever before.  The importance of Cyclosporine A 
may be best illustrated by the fact that prior to its inception, transplant of hearts, lungs, 
and livers were rare clinically, as these organs were much more susceptible to rejection 
with previous immunosuppressive therapies.  Though Cyclosporine A signaled the dawn 
of effective immunotherapeutics for transplant patients, the application of transplant to 




another significant barrier to survival of non-kidney grafts—organ preservation.  Though 
now of greater clinical relevance, the problem of organ preservation was understood by 
surgeons from the very beginning of transplant research, as one of the most significant 
findings of Carrel and Guthrie’s first heart transplant was that a heart could resume 
contraction upon reperfusion.  However, it was clear then, as now, that preservation 
techniques sufficient for intra-abdominal grafts (kidney and liver) were less effective in 
the preservation of intra-thoracic grafts (heart and lung) (61).   
The earliest attempts at organ preservation utilized machine-operated perfusion.  
The machines were bulky and expensive to operate and significantly limited the 
procurement of donor organs.  Fortunately by the late 1960s, Geoff Collins and Paul 
Terasaki had demonstrated that kidneys could be successfully stored by flushing with a 
specialized solution intended to more closely resemble intracellular solution conditions  
and storing on ice (62), similar to the method employed by Lower and Shumway (25).  
Indeed Terasaki went on to show that similar results to machine-driven perfusion could 
be obtained with iced storage, making the transport of donor organs faster and cheaper, as 
specialized equipment was no longer required (63).  By the mid 1970s a majority of 
clinics were using Collins’ technique to preserve kidneys (61).  Though numerous 
iterations attempting to improve the preservation times of organs by both machine 
perfusion and cold storage, no approach emerged as better than the others throughout the 
1970s (61).  However, in 1986, a group working at organ preservation at University of 
Wisconsin at Madison introduced the UW solution.  What set this preparation apart from 




improve the survival rates of the liver, kidney, pancreas, intestine, lung, and heart (64), 
though there is still room for improvement (65).   
 Soon after the UW solution revolutionized organ perfusion, another milestone in 
immunosuppressive drugs became available.  A group from the Fujisawa Pharmaceutical 
Company isolated a soil fungus, Streptomyces tsukubaensis, from the Tsukuba region of 
northern Japan whose fermentation supernatant exhibited potent immunosuppressive 
capacity in their high throughput screen for molecules able to phenocopy Cyclosporine A 
(66, 67).  The structure of the compound was determined and in August of 1986 the 
group presented their discovery of FK506 (Tacrolimus) for the first time (68).  
Subsequent investigation showed that FK506 was effective at far lower concentrations 
than Cyclosporine A, and could be potentially synergize with Cyclosporine A by 
potentiating its binding and uptake by lymphocytes with no obvious additive toxicity (69-
71).  Early evidence also pointed to a common intracellular target for both drugs (72).  
The subsequent discovery that FK-506 targets the T cell signaling intermediate 
calcineurin marks the first successful application of forward chemical genetics to 
elucidate a signaling pathway (67).   
FK506 exhibited side effects, particularly in dogs, not seen with Cyclosporine A, 
though it appeared less toxic in initial primate studies (73, 74).  Based on these findings, 
Thomas E. Starzl initiated clinical trials with FK-506 in liver transplant patients who 
were unresponsive to traditional immunotherapy (75).  The ability of FK-506 to act as a 
―rescue agent‖ in transplant settings (76) was likely an important factor in the eventual 




explanation for the effectiveness of FK506 was that it is far less susceptible to removal 
from the cell by the multi-drug resistance gene, p-glycoprotein, than Cyclosporine A was 
(78).  Further, p-glycoprotein mediated resistance to Cyclosporine A may be exacerbated 
in vivo, as therapeutic doses of Cyclosporine A can actually induce the expression of p-
glycoprotein in certain cell types (79).  The availability of multiple drugs to treat 
rejection and their known toxicities (70, 80-84) prompted the current use of 
combinatorial therapies aiming to optimize immunosuppression while minimizing side 
effects of the drugs.    
FK-506 prompted the re-investigation of another drug, Rapamycin (Sirolimus), 
whose immunosuppressive function was originally discovered in 1977 (85).  An 
important common characteristic of Rapamycin and FK-506 is the ability to reverse the 
multidrug resistance phenotype (78).  Another key immunosuppressive drug to emerge 
after FK-506 was Mycophenolate mofetil, which was originally used to treat psoriasis in 
1975 (86), but introduced to transplantation later with the first clinical trials aimed at 
determining whether or not the drug could replace azathioprine in the heart transplant 
―triple therapy‖ with Cyclosporine A and steroids (87).  The effectiveness of 
Mycophenolate mofetil in this and other clinical trials rapidly raised interest in the drug.  
This interest was augmented by the discovery that it’s method of action—sabotage of de 
novo purine biosynthesis—is quite specific to rapidly dividing lymphocytes as many 
other cells utilize the metabolic purine salvage pathway facilitated by hypoxanthine 
ribosyltransferase (88-90).  Hence, Mycophenolate mofetil replaced azathioprine in the 




treatment.  Frequently the ―triple therapy‖ is augmented by antibody treatments (Figure 
3) (91). 
 
Figure 2  Summary of Modern Immunosuppressive Approaches 
 






Chapter II—Transplantation Today 
  
Acute Rejection 
An overview of transplant history clearly traces a progression of advances in 
transplant techniques and immunosuppressive therapeutics.  Prior to the advances in 
immunosuppressive drugs, grafts were largely lost due to acute rejection characterized by 
intense perivascular infiltrate and parenchymal cell death (92).  Acute allograft rejection 
remains a challenge to clinical organ transplant today and can occur through several 
different immunologic mechanisms.  In some cases, acute graft rejection can be the result 
of preformed graft-reactive antibodies in the organ recipient (93-96).  Indeed, antibodies 
can also play an important role in acute rejection even when not preformed.  In addition 
to antibody-mediated acute rejection, acute rejection often occurs through cell-mediated 
immunity.  It should be noted that acute rejection can occur through humoral or cellular 
immunity and can be associated with multiple effector lineages, including Th1 and Th2 
(illustrated in Figure 6).  Today, fewer transplants are lost owing to the effectiveness of 




Though modern therapies are excellent at limiting acute rejection and prolonging 
short-term graft survival, a true evaluation of the success of clinical transplantation must 
take long term survival into account—and therein, as Hamlet would tell us, lies the rub.  
Current estimates place the rate of cardiac graft failure at approximately 5% annually 
(97).  The most significant barrier to long term graft survival is chronic rejection (CR) 
(98-103), which may be present to varying degrees in up to 80% of grafts by 5 years post 
transplant (104).   
Chronic Rejection 
The definition of CR remains somewhat ambiguous, and CR is often used to 
describe all graft loss after one year.  It has been proposed that CR should specify late 
graft failure due to anti-graft immunity, which is then subdivided into parenchymal cell 
CR (associated with fibrosis of graft parenchyma) or vascular CR (associated with 
vascular stenosis caused by neointimal development) (105).  A concise definition of CR 
is further complicated by the understanding that both immune and non-immune 
parameters contribute to CR (106).  However, any rigid classification is plagued by 
questions as to whether or not alloantigen-dependent immunologic events are separable 
from alloantigen-independent responses.  Therefore, CR in this manuscript will be 
defined by three hallmarks—progressive deterioration of graft function, interstitial 
fibrosis, and occlusion of luminal structures. 
Though CR is the most common form of late graft failure in solid organ transplant 
(98-103), its etiology is not well understood.  Numerous factors contribute to or have 




of two non-exclusive categories:  alloantigen-dependent or alloantigen-independent (98, 
101, 103, 107).  Searches for early biomarkers of CR in transplanted organs have 
provided limited causative results.  However, factors that have been reported to correlate 
with late graft loss include excessive graft work load (108-110), donor related factors 
such as diabetes, arteriosclerosis, and cause of donor death (60), history of acute rejection 
(110-112), circulating donor antigen (113), infection (114, 115), duration of cold 
ischemic time (116), and measures of allograft immunity (111, 113).  Though these and 
other factors may be biomarkers of CR risk, each has barriers to clinical utility.  For 
example, with respect to previous acute rejection episodes, not all types of acute rejection 
episode are equivalent in elevating the risk of chronic rejection at later time points (117-
119).  In addition, other reports have questioned the validity of previous rejection 
episodes as a predictor for later development of CR (120).  Diagnosis is further 
complicated by specific measures of graft alloimmunity, such as anti-HLA antibodies, 
that can be observed in both patients undergoing CR as well as those that are not 
experiencing rejection (121-123), though anti-idiotype antibodies are present in the non-
rejecting group which may abrogate the anti-graft response.  Thus, reliable prediction and 





Figure 4  Factors Implicated in CR 
Chronic Allograft Vasculopathy (CAV) 
Though prediction of CR by risk factor and immunologic analyses is considerably 
difficult, the assessment of transplant vasculature can provide additional information 
about the state of transplanted organs.  The occlusive vascular disease associated with CR 
of cardiac grafts in humans was first reported in 1970 (124).  Several reports suggest that 
some level of intimal thickening can be observed in 75% of cardiac transplants within the 
first year post transplant (125, 126) which may then develop CAV, estimated to occur in 
up to 80% of cardiac transplants within the first 5 years post-transplant (104, 127).  The 




transplant associated vasculopathy, transplant-associated coronary artery disease, 
transplant arteriosclerosis, graft coronary artery disease, chronic transplant dysfunction, 
graft coronary vascular disease, transplant coronary artery disease, and accelerated graft 
arteriosclerosis, and likely others.  CAV can manifest as two distinct vascular pathologies 
(Figure 3), intimal remodeling and constrictive remodeling.   
 
Figure 5  Vascular Remodeling in CR 
For some time it was presumed that hyperplasic thickening of the vascular intima, also 
known as neointima, was the primary manifestation of CAV (105).  However, this 
assumption was challenged by several studies utilizing intravascular ultrasound in which 
consistent constrictive remodeling was observed (128, 129).   Recently, extensive 
investigations with intravascular ultrasound have indicated that the process of luminal 
occlusion in CAV may be a biphasic process with intimal thickening occurring first 




Currently, no effective therapeutic exists for CAV other than retransplantation 
(133), a dubious therapeutic considering the constant global donor organ shortage.  The 
current clinical approach to CAV is prevention—though this has largely been ineffective 
as Cyclosporine A, azathioprine, steroids, and antilymphocyte antibodies have yet to 
decrease the incidence of the disease (103).  Recently, improvement in the incidence and 
severity of CAV has been observed with the newest immunosuppressive treatments, 
including Mycophenolate mofetil (131), Sirolimus (134), and Everolimus (103).  
However, there is no direct evidence that these treatments specifically target CAV 
associated with CR, but rather may generally provide prevention through more robust 
immunosuppression, as in some cases acute rejection was decreased as well (135, 136).  
Thus, in spite of advancements in immunotherapeutic approaches, CR remains the 
leading cause of death after the first year following cardiac transplantation and the 
greatest barrier to the effective use of available donor organs in the clinic (137).  
Transplant Immunology in CAV 
CAV affects arteries and veins of the graft up to, but not beyond, the suture line of 
the graft (103).  This supports the widely held notion that graft-derived factors, likely 
donor alloantigens, play a critical role in the disease  (98, 99, 101-103, 106).  Recognition 
of donor alloantigens can occur through multiple pathways, in all of which T cells play a 
critical role (138).  It should be noted that T cell recognition of foreign antigens alone 
renders T cells in a state of anergy (139), while allorecognition in the context of T cell 
costimulatory molecules can trigger a robust alloimmune response.  Because T cell 




may trigger alloimmune responses.  These cellular interactions are typically referred to as 
the direct and indirect pathways (140), though recent evidence suggests the possibility of 
a semidirect pathway (141) and direct endothelial activation (142).  In the direct pathway 
of allorecognition, donor MHC molecules presented by a donor antigen presenting cell 
(APC) are recognized by an alloreactive T cell (143) (Figure 6).   
 
Figure 6  Immunobiology of Transplant Rejection 
Allorecognition of foreign peptide in the context of self or foreign MHC molecues 
by the T cell receptor provides an initial signal to the T cell which then receives 
secondary activation through costimulation signals including CD40/CD40L interactions, 
then CD28 with B7-1 or B7-2 (CD80 or CD86) (144) and LFA-3/CD-2 (145, 146) 




subsequent adaptive immune responses.  The indirect pathway involves the uptake of 
donor antigen by recipient APCs, which then present the processed donor peptide in the 
context of ―self‖ MHC molecules (147, 148).  The APC may then provide the necessary 
T cell signaling and costimulation described above to prime an adaptive immune 
response.  In the semidirect pathway, contact between donor cells and a host APC results 
in transfer of donor MHC molecule(s) to a host APC cell membrane (141, 149, 150).  The 
host MHC can then present the foreign MHC and peptide similarly to how a donor origin 
APC would in the aforementioned direct pathway.  The fourth mechanism of 
allorecognition is that of direct endothelial activation (142, 151), the most controversial 
mechanism of alloimmune T cell priming (152).  Though human endothelial cells 
generally express LFA-3 (153) and cultured primary cardiac microvascular endothelial 
cells can express B7-2 following ligation of CD40 (154), the ability of endothelial cells to 
provide canonical costimulatory signals sufficient for priming in vivo remains to be 
demonstrated.  Therefore, graft endothelial cell activation of T cells may likely provide 
reinforcement and augmented cytokine production by cells activated through other 
cellular interactions rather than priming the de novo differentiation of allogeneic T cells 
(155, 156) (Figure 6).  In summary, it remains unclear which alloreactive pathways 
provide the greatest contribution to the pathology of CAV in CR of heart allografts, 
though there is experimental evidence for both indirect (157-159) and suboptimal direct 
(160) allorecognition being sufficient to promote CR. 
Many studies have attempted to elucidate the immunologic component 




vasculature through repeated immune cell attack, representing ―smoldering, subacute 
rejection accumulating progressive subclinical (low level) damage‖ (105).    If this 
hypothesis is indeed correct, it would be of great value to know which cell types are 
responsible for ―smoldering‖ damage to the graft.  In addition to the increased amounts of 
smooth muscle cells (161-163), endothelial cells (164) and fibroblasts (165) in vessels 
undergoing CAV, there are infiltrating immune cells including monocytes/macrophages 
(163, 166), dendritic cells (138), and T cells (163, 167, 168).  One of the most thorough 
investigations into the immune cells required for CAV was performed in a model of 
carotid artery transplant across multiple histocompatibility barriers (169).  The 
transplants into seven previously characterized mutant mouse strains allowed for the 
transplantation of coronary arteries into recipients deficient in all antigen specific 
responses (170), responses by CD4
+
 T cells (171, 172), B cells (173), cytotoxic T cells 
(174), natural killer cells (175), and macrophages (176).  This investigation highlighted 
the importance of antigen specific responses in the development of CAV and in particular 
that full CAV pathology required CD4
+
 T cells, B cells, and macrophages (169).  
Subsequent studies have generally supported the finding that multiple types of immune 
responses are required for the initiation and progression of CR, particularly the necessity 
of CD4
+
 T cells (177) and macrophages (178), while anti-allograft antibody remains 
somewhat controversial (179, 180).   
In summary, current understanding of CAV has been characterized as 
immunologic attack on endothelial cells that triggers subsequent healing responses (164), 




(182).  These processes may in turn produce a cytokine milieu amenable to smooth 
muscle cell recruitment (183) and proliferation, progenitor cell recruitment (184, 185), 
and myofibroblast transdifferentiation (186-188) culminating in CAV. 
Graft Fibrosis 
The changes associated with CR also include interstitial fibrosis (Figure 2), 
another hallmark of CR pathology, the early extent of which correlates with long term 
transplant outcome (189).  Fibrosis of hearts undergoing CR is characterized by the 
formation of thick web-like interstitial extracellular matrix (ECM) fibers surrounding 
cardiomyocytes.    It has been suggested that graft fibrosis occurs largely in response to 
CAV (103), though the relationship between these elements of graft pathology is not 
known.  Cardiac fibrosis is frequently divided into two types, reactive and reparative 
(190-193).  Reactive fibrosis generally occurs first in response to stimuli such as 
cytokines and hypertension while reparative is believed to occur in response to cell death 
(192, 194, 195).  The increased ECM accumulation in the fibrotic heart has multiple 
implications for graft function, as it provides increased tensile strength, but also stiffness, 
to the myocardial wall while the sheathing of individual cardiomyocytes with ECM alters 
cell to cell contacts.  These changes result in disruption of the electophysiology of cardiac 
myocytes (194) and likely decreases in the energy supply of cardiomyocytes, all while 
the workload for graft contractility is increased (195).  The intense stress of such 
conditions leads to cell death, which in turn triggers additional reparative fibrosis and 





Enhanced ECM accumulation seen in tissue fibrosis is the result of two competing 
programs—those that promote the synthesis of ECM and those that promote ECM 
degradation (196, 197).  The two major components of cardiac ECM are collagen types I 
and III (198, 199).  Both types of collagens provide support and structure to the healthy 
heart, though type I collagen is characteristically associated with thick fibers which are 
thought to play a central role in determining myocardial stiffness (199).  Hence, collagen 
type I abundance is frequently used as a surrogate index for the degree of fibrosis in heart 
tissues as well as those of other organs.  While the accumulation of ECM in allograft 
fibrosis is readily observable, the cellular source of excessive ECM proteins is less clear.  
It was reported that cardiac myocytes can contribute to the production of collagen type I 
(200, 201) in addition to production of non-filamentous type IV collagen in their 
basement membranes (202), though it is generally accepted that the cell that regulates 
homeostasis of ECM within the heart is the fibroblast (202).  Cardiac fibroblasts are an 
abundant cell type in cardiac tissue (203, 204) and are a fixture of the cardiac ECM that 
facilitates structural and functional connections in healthy cardiac tissue (203, 205).   
Stages in Fibrosis Development 
 The progression of graft fibrosis can be described as occurring in three general 
stages (100).  The first stage involves the initiation of the fibrotic response.  Initiating 
factors for fibrotic responses can include both alloantigen-dependent (cellular and 
humoral immune attack) and alloantigen-independent factors (health of graft, ischemia 




damage.  Tissue damage prompts what has been referred to as the fibrogenesis phase, 
characterized by the production of signaling mediators including cytokines, chemokines 
and growth factors (206, 207).  These mediators initiate at least three cellular responses in 
the graft.  First, cytokines and chemokines promote infiltration by non-graft immune 
cells, fibroblasts (208), and progenitor cells (209, 210).  Infiltrating cells can further 
enhance production of cytokines and growth factors that drive a proliferative response in 
inflammatory cells, fibroblasts and epithelial cells.  In addition to proliferative responses, 
cytokines and growth factors prompt the third phase by promoting the differentiation of 
cells into other cell types (188).  The occurrence of endothelial to mesenchymal 
transformation correlates with later development of graft fibrosis (211).  Though the 
differentiation of several cell types can be initiated in response to cytokines associated 
with the fibrogenesis phase, perhaps the most important cell type with respect to 
accumulation of ECM associated with CR may be those expressing fetal smooth muscle 
isoform α actin (212, 213), a marker associated with myofibroblasts (214, 215). 
Myofibroblasts 
Myofibroblasts are a specialized form of activated fibroblast first described in the 
process of cutaneous wound healing (216).  Myofibroblasts are characterized by 
phenotypic features associated with the process of wound closure, namely the expression 
of α-smooth muscle actin (αSMA), intermediate filament proteins such as vimentin and 
desmin, and non-muscle forms of myosin (188, 202, 217, 218).  The presence and 
persistence of myofibroblasts have been associated with alloantigen mismatch-driven 




been extensively linked to myocardial remodeling in response to cardiac cell death (220, 
221).  While more evidence exists to indicate the importance of myofibroblast 
differentiation and migration in response to myocardial infarction (222, 223), persistent 
myofibroblasts have been observed in interstitial infiltrate of kidney grafts undergoing 
CR (224, 225) and early increases in myofibroblasts may be predictive for kidney grafts 
that will later develop CR (226).  Indeed, the lack of characterization of the role of 
myofibroblasts in CR of cardiac grafts may owe to the ability of myofibroblasts to 
acquire markers commonly associated with muscle differentiation, which obfuscates their 
identification in smooth muscle-rich cardiac vasculature (227).  Interestingly, increases in 
myofibroblasts have been observed in response to acute cardiac rejection (214) as well as 
in response to oxygen flux that may represent conditions of ischemia/reperfusion injury 
(228).   
Interstitial fibrosis has several effects on the myocardium of cardiac grafts that 
can generally be considered to inhibit function.  Further, effects of cardiac myofibroblasts 
may extend to modulation of electrical impulses in the heart (229, 230).  In addition to 
the effects of myofibroblasts on the production of ECM, fibroblasts can themselves 
function as inflammatory cells, producing cytokines, chemokines and growth factors 
(231).  Indeed there is considerable evidence for interplay between fibroblasts regulating 
immune activation and the course of inflammatory responses (232).  Further, activated 
fibroblasts can express costimulatory CD40 (233) and cardiac myofibroblasts respond to 
inflammatory cytokines such as tumor necrosis factor-α, IL-1, IL-6, and TGFβ (234, 




that enhances further infiltration and dysfunction through the production of immune 
cytokines, chemokines and growth factors.   
Factors associated with CR 
TGFβ 
Multiple factors have been associated with its onset and progression, especially 
TGFβ.  TGFβ overexpression is linked with chronic rejection (236, 237), and may 
negatively impact graft survival through chemotactic and pro-fibrotic effects (238).  
TGFβ plays an important role in fibrosis of various causes in multiple organs (239).  
TGFβ is known to induce the differentiation of cardiac myofibroblasts (240), though this 
process is dependent upon osteopontin in cardiac and dermal fibroblasts (226).  Further, it 
is likely that cardiac myofibroblast differentiation depends on cell adhesion and the extra 
domain A containing splice variant of fibronectin as in other myofibroblast precursors 
(241-243).  It should be noted that fibroblasts themselves can make TGFβ (244) and 
myofibroblasts are rescued from apoptosis by TGFβ (245). 
In addition to its deleterious fibrotic effects on the graft, TGFβ-mediates 
immunosuppressive and anti-proliferative functions that may be indispensable for graft 
and host survival (246).  For example, TGFβ plays a critical role in the induction and 
function of T regulatory cells (Treg), which are believed to contribute to graft acceptance 
(247-249).  Further, TGFβ inhibits T and B cell proliferation (238) and represses cancers 
of epithelial cell origin (250). These opposing effects make TGFβ a suboptimal target for 




in CR pathology.  Identifying downstream mediators of CR may facilitate the 
development of therapeutics that negate the fibrosis-inducing activity of TGFβ while 
sparing its anti-inflammatory and anti-proliferative effects. 
Connective Tissue Growth Factor (CTGF) 
CTGF is induced by TGFβ in multiple cell types (251), including cardiac 
myocytes and fibroblasts (252) (Figure 4).   
 
Figure 7  CTGF is induced by TGFβ 
CTGF plays an important role in the development of connective tissue as well as the 
formation of scar tissue (253, 254), and is upregulated in multiple fibrotic disorders, 
including CR of cardiac and kidney grafts (236, 255-257).  CTGF mediates multiple pro-




proliferation, and enhancement of adhesive responses (257).  Recently, the ability of 
CTGF to potently stimulate neointimal hyperplasia associated with vascular injury has 
been illustrated by findings that exogenous application of CTGF recapitulates the 
phenotype of TGFβ signaling mediator SMAD3 gene transfer (258).  This suggests that 
CTGF may be a critical mediator of TGFβ effects in vascular injury.  Thus, as CTGF is 
induced by TGFβ and because CTGF mediates pro-fibrotic effects and remodeling effects 
associated with TGFβ, CTGF has been proposed as a therapeutic target for limiting the 
deleterious fibrotic effects of TGFβ while sparing its immune-modulatory functions (100, 
236, 259).   
CTGF induction by TGFβ has been observed in settings of cardiac fibrosis (257), 
though transduction of syngeneic grafts with TGFβ is insufficient to induce CTGF or CR 
(236).  Hence, TGFβ-mediated induction of CTGF in vivo is contextually dependent.  
One such contextual difference between allogeneic and syngeneic grafts is the 
development of alloimmune responses which may provide factors that crosstalk with 
TGFβ signaling (260).  One such factor, investigated in this dissertation, is IL-6, a 
cytokine that modulates the effects of TGFβ in multiple cell types (261-263). 
Dissertation Overview 
 The overarching aim of these studies was to better understand factors influencing 
the pathology of CR of cardiac grafts.  The initial aims were specifically to determine if 
the beneficial aspects of TGFβ (immunosuppressive and anti-proliferative effects) could 
be separated from the deleterious aspects (proinflammatory and profibrotic effects) in the 





Figure 8  Potential TGFβ Effects in Cardiac Grafts 
In the process of investigating the initial aim, these studies have uncovered a critical role 
for IL-6 in the induction of CTGF, and CTGF is demonstrated to function as a 
downstream mediator of TGFβ-mediated fibrosis.  Further, these studies utilized several 





Chapter III—Materials and Methods 
Mice 
WT female C57BL/6 (H-2
b
) and BALB/c (H-2
d
) mice were purchased from 
Charles River Laboratories (Raleigh, NC).  The animals were kept under micro-isolator 
conditions.  The use of mice for these studies was reviewed and approved by the 
University of Michigan’s Committee On The Use And Care Of Animals. 
 
Vascularized Cardiac Transplantation 
Heterotopic cardiac transplantation was performed as described (264).  Briefly, 
the aorta and pulmonary artery of the donor heart were anastomosed end-to-side to the 
recipient’s abdominal aorta and inferior vena cava, respectively. Upon perfusion with the 
recipient’s blood, the transplanted heart resumes contraction.  Graft function is monitored 
by abdominal palpation. 
 
In Vivo mAb Therapy 
Anti-CD4 (hybridoma GK1.5¸ obtained from American Type Culture Collection, 
Manassas, VA), anti-CD40L (hybridoma MR1, kindly provided by Dr. Randy Noelle, 
Dartmouth College), and anti-IL-6 mAb (hybridoma MP5-20F3, obtained from American 




by Bio X Cell (West Lebanon, NH).  Allograft recipients were transiently depleted of 
CD4+ cells by i.p. injection of 1 mg of anti-CD4 mAb on days -1, 0, and 7 post transplant 
(236, 265).  For inductive anti-CD40L therapy, allograft recipients were injected i.p. with 
1 mg of anti-CD40L on days 0, 1, and 2 post transplant (236, 265).  Anti-IL-6 mAb or 
control rat IgG (Sigma, St. Louis, MO) was administered by i.p. injection of 1 mg on 
days -1, 1, and 3 and weekly thereafter (265, 266).  Allograft recipients treated with anti-
CTGF mAb (FG-3019, kindly provided by FibroGen, Inc., San Francisco, CA (267, 268)) 
or control human IgG (Sigma, St. Louis, MO) received 0.5 mg i.p. twice weekly 
beginning on day 7 postransplant. 
 






Figure 10  2D Echocardiography Technique 
Serial non-invasive echocardiography was performed with a 30 MHz ultrasound 
probe (Vevo 770, VisualSonics Inc., Toronto, Canada).  Mice were anesthetized using 
inhaled isofluorane.  Anatomical and functional changes were assessed in the left 
ventricle (LV) of heterotopic cardiac grafts by obtaining short-axis views (at the mid-
papillary level) of the grafts as reported by Scherrer-Crosbie et al. (269).  Briefly, 
echocardiographic images were recorded in real time from both axial and longitudinal 
axes and saved for subsequent analysis.  Measurements of posterior wall thickness 
(PWT) were performed in diastole and measurements for calculating fractional 




technique was validated by measuring PWT of acutely rejecting BALB/c allografts in 
C57BL/6 recipients, and in syngeneic C57BL/6 controls as described (269).  
Echocardiography was performed on allografts in recipients transiently depleted of CD4+ 
cells (which develop CR), allograft recipients given anti-CD40L mAb therapy (which do 
not develop CR), and syngeneic C57BL/6 graft controls.  Serial echocardiography was 
performed to evaluate PWT, FS and left ventricle ejection fraction (LVEF).  
Measurements were obtained on day 7 and then weekly from day 21 to day 49 post 
transplant. 
Adenoviral-mediated transduction of cardiac grafts 
Transduction was performed as previously described (236, 270, 271).  Briefly, 
cardiac grafts were perfused via the aorta with 5 × 10
8
 pfu of E1/E3 deleted adenoviral 
vectors encoding the active form of human TGFβ1 (AdTGFβ) (236, 270), human CTGF 
(AdCTGF) (272), or beta-galactosidase (Adβgal) (236, 270, 271).  Following perfusion, 
donor grafts were placed in iced Ringer's solution for 1 hour prior to transplantation.  
Previous studies with Adβgal have revealed a patchy distribution of transgene expression 
by both cardiac and vascular cells that persists for at least 8 weeks post transplant (271). 
Morphometric analysis of cardiac graft fibrosis and hypertrophy 
Graft fibrosis was quantified by morphometric analysis of Masson’s trichrome 
stained sections using iPLab software (Scanalytics Inc., Fairfax, VA).  Mean fibrotic area 
was calculated from 10 to 12 areas per heart section analyzed at 200X magnification 
(265, 273).  To quantify cardiomyocyte area as a measure of hypertrophy, digital outlines 




200X magnification.  Areas within outlines were quantified using SCION IMAGE Beta
 
4.0.2 software (Scion Corporation, Frederick, MD) to measure cardiomyocyte cell size 
(274).  A minimum of 8 hearts were analyzed per group for both analysis techniques. 
Quantitative real time PCR  
Graft RNA was isolated by homogenizing tissues in TRIzol reagent (Invitrogen, 
Carlsbad, CA) as per manufacturer’s protocol.  Five µg of total RNA were reverse 
transcribed using Oligo dT, dNTPs, MMLV-RT (Invitrogen, Carlsbad, CA), RNAsin 
(Promega, Madison, WI) in PCR Buffer (Roche, Indianapolis, IN).  Resulting cDNA was 
purified by a 1:1 extraction with phenol/chloroform/isoamyl (25:24:1) then precipitated 
in one volume 3M NaOAc and two volumes absolute ethanol.  Levels of atrial natriuretic 
peptide (ANP), CTGF, IL-6, TGFβ, IL-17, and T cell receptor β constant region (TCRβ) 
message were determined by quantitative real time PCR using iQ SYBR master mix 
(Bio-Rad, Hercules, CA) in a Rotor-Gene 3000 thermocycler (Corbett Life Science, San 
Francisco, CA).  Expression levels were determined relative to GAPDH using the Rotor-
Gene Comparative Concentration utility. 
Primer sequences were as follows:   
ANP (Nppa) forward 5’ GGAGGTCAACCCACCTCTG 3’  
ANP (Nppa) reverse 5’ GCTCCAATCCTGTCAATCCTAC 3’  
CTGF (Ctgf) forward 5’ GGAAAACATTAAGAAGGGCAAAA 3’ 
CTGF (Ctgf) reverse 5’ CCGCAGAACTTAGCCCTGTA 3’ 
GAPDH (Gapdh) forward 5’ CTGGTGCTGAGTATGTCGTG 3’  




IL-6 (Il6) forward 5’ CGTGGAAATGAGAAAAGAGTTGT 3’  
IL-6 (Il6) reverse 5’ TCCAGTTTGGTAGCATCCATC 3’ 
TGFβ (Tgfb 1) forward 5’ CCTGAGTGGCTGTCTTTTGAC 3’ 
TGFβ (Tgfb 1) reverse 5’ CCTGTATTCCGTCTCCTTGGT 3’ 
IL-17 (Il17a) forward 5’ GGACTCTCCACCGCAATGA 3’ 
IL-17 (Il17a) reverse 5’ GACCAGGATCTCTTGCTGGA 3’ 
TCRβ (Tcrb-C) forward 5’ CTGCCAAGTGCAGTTCCAT 3’ 
TCRβ (Tcrb-C) reverse 5’ GGCCTCTGCACTGATGTTCT 3’ 
Flow cytometry 
Splenocytes were labeled with FITC-conjugated anti-CD3, PE-conjugated anti-
CD4, and CY5-conjugated anti-CD8 (PharMingen San Jose, CA).  Cell analyses were 
performed on lymphocytes gated using forward vs. side scatter using a Becton Dickinson 
FACSCalibur (San Jose, CA). 
Statistical analysis  
Statistical significance was calculated using an unpaired t-test with Welch’s 







 BALB/c cardiac allografts in C57BL/6 recipients receiving anti-CD40L mAb 
continue to function for >60 days and do not develop CR, unless transduced with TGFβ 
(236).  In contrast, allografts in recipients transiently depleted of CD4+ cells develop CR 
as CD4+ cells begin to repopulate the periphery between 3 and 4 weeks following initial 
depletion (236, 275-277).  Hence, we compared events that occurred in these two settings 
to identify critical elements associated with the progression of CR.  Specifically, we 
assessed anatomical and functional echocardiographic parameters, cardiac hypertrophy, 
intragraft IL-6 expression, and graft fibrosis in CR.  Echocardiographic and histologic 
analysis revealed that day 30 post transplant represents a critical point in this CR model 
as extensive graft hypertrophy and fibrosis are present at this time and are followed by 
degradation of cardiac contractility (265).  Therefore, for most experiments grafts were 
assessed at day 30 post transplant in these studies. 
Fibrosis in allografts undergoing CR 
Fibrosis was most prominent among grafts transiently depleted of CD4+ cells that 
develop CR as assessed by morphometric trichrome analysis (p<0.0001, Figure 6).  




significant changes were found in either graft fibrosis (Figure 6B) or collagen αI 
transcripts (Appendix 1) between day 30 and day 50 post transplant in grafts undergoing 
CR, indicating a full fibrotic response by day 30 in this model. 
 
Figure 11  Fibrosis is Increased in Cardiac Grafts Undergoing CR.  (A) Representative Masson's 
trichrome stains, in which fibrotic tissue stains blue, of heterotopic cardiac grafts at day 30 post 
transplant (200x magnification). Cardiac allografts from recipients transiently depleted of CD4+ cells 
(Anti-CD4) or allograft recipients receiving anti-CD40L mAb therapy (Anti-CD40L) are shown 
along with syngeneic control grafts. (B) Morphometric analysis of trichrome staining at day 30 and 
50 post transplant in groups from (A). Bars represent the combined mean + S.E.M. of fibrotic (blue) 
area of 10–12 frames of view per heart taken from no fewer than 6 different cardiac grafts per group. 
Echocardiographic assessment of the progression of CR   
Serial echocardiography was performed to determine the anatomical and 
functional changes associated with the progression of CR.  This echocardiographic 
technique was validated by assessment of unmodified syngeneic and allogeneic grafts as 
previously described (269).  Increases in PWT in acutely rejecting allogeneic grafts as 




results (269) in both trend and magnitude (data not shown).  It should be noted that LV 
intra-cavity thrombosis was observed in all groups.  Following the first week post 
transplant, intra-cardiac thrombus retraction (toward the apex) occurred, allowing lucid 
visualization of all LV parameters as endocardial contour definition was clearly 
demarcated. 
Echocardiography was used to monitor allografts in recipients transiently depleted 
of CD4+ cells, which undergo CR.  Although it is true that heterotopic cardiac grafts 
contract against a reduced load, identical surgical procedure between groups assures 
similar loading conditions required for comparative assessments of graft hypertrophy and 
fibrosis.  Allografts undergoing CR were compared to allografts in recipients receiving 
anti-CD40L therapy (that do not undergo CR) and also to syngeneic grafts (Figure 7).  
PWT was greatest in grafts undergoing CR from day 7 through day 49 post transplant, 
peaking at approximately day 35 (Figure 7A).  The increase in PWT among CR grafts 
correlated with an increased FS and LVEF (Figure 7).  These parameters remained stable 





Figure 12  Echocardiographic analysis suggests hypertrophy in grafts undergoing CR. Serial 
echocardiography was used to monitor anatomical and functional parameters of cardiac allografts in 
recipients that were transiently depleted of CD4+ cells (Anti-CD4, squares), in allograft recipients 
receiving anti-CD40L mAb therapy (Anti-CD40L, triangles), or syngeneic graft recipients (circles). 
Echocardiographic parameters included posterior wall thickness (PWT) (A), fractional shortening 
(FS) (B), and left ventricle ejection fraction (LVEF) (C). Three transplants per experimental group 
were followed throughout the duration of the experiment. Individual points represent mean and bars 
represent ± S.E.M. at the given time points. *Day 35: Anti-CD4 vs. Anti-CD40L, p= 0.004 and Anti-
CD4 vs. Syngeneic, p= 0.017. ‡ Day 49: Anti-CD4 vs. Anti-CD40L, p= 0.0126 and Anti-CD4 vs. 
Syngeneic, p= 0.0146. 
Increases in PWT and cardiac functional parameters (FS and LVEF) by day 35 post 
transplant in the anti-CD4 treated group suggested an association of cardiac hypertrophy 
with CR.  Following the peaks in PWT, FS and LVEF at day 35 post transplant, 
deterioration of graft contractility occurred by day 42 (Figure 7B and C).  Together, the 




7B and C) and the consistency of graft fibrotic area over the same time period (Figure 
7B) indicated that day 30 represents a critical time point in this CR model.   
Cardiomyocyte hypertrophy and elevated IL-6 expression in grafts 
undergoing CR  
Echocardiography revealed an anatomical increase in PWT as well as functional 
increases in FS and LVEF, factors consistent with a hyperdynamic state, as is seen with 
LV hypertrophy.  Cardiac hypertrophy has been defined as an increase in heart mass 
reflective of increased cell size rather than cell number (278).  To verify the presence of 
hypertrophy, cardiomyocyte areas were evaluated histologically at day 30 post transplant 
(Figures 8A and B).  Histologic analysis revealed that cardiomyocyte size was greatest in 
CR grafts when compared to allografts in recipients receiving anti-CD40L or syngeneic 
grafts (p<0.0001).  Further, because increased levels of ANP expression have been 
correlated with cardiac hypertrophy (279, 280), intragraft expression of ANP was 
determined with quantitative real time PCR.  Intragraft ANP expression correlated with 
cardiomyocyte size in CR grafts, allograft recipients receiving anti-CD40L mAb, and 





Figure 13  Histologic confirmation of cardiac hypertrophy in CR grafts. (A) H&E stains of day 30 
post transplant cardiac allografts taken from recipients transiently depleted of CD4+ cells (Anti-
CD4) or recipients receiving anti-CD40L mAb therapy (Anti-CD40L) as well as syngeneic control 
graft recipients. Arrows highlight representative cardiac myocytes. (B) Cardiomyocyte areas were 
quantified using morphometric analysis. Bars represent mean + S.E.M. of area measurements taken 
from at least 80 cardiomyocytes per heart from 5 different hearts per group. (C) Intragraft message 
levels of atrial natriuretic peptide (ANP), a marker of cardiac hypertrophy, were measured with 
quantitative real time PCR in cardiac grafts from recipients in (B) at day 30 post transplant. Bars 
represent mean + S.E.M. of 3–5 grafts per group. 
Since cardiac hypertrophy coincided with increased fibrosis in CR allografts, we 
hypothesized that there might be a common immunologic mediator of both processes.  
IL-6 has been linked to cardiac hypertrophy (281) and collagen production (282).  
Therefore, IL-6 expression was assessed in allografts undergoing CR, as well as in 
control grafts.  IL-6 message levels were highest in CR grafts at all time points (Figure 
9).  While intragraft IL-6 message levels progressively decreased after day 7 among 
allografts treated with anti-CD40L and syngeneic grafts, CR grafts exhibited a significant 




correlation was observed between CD4+ cell return (275, 276), intragraft IL-6 
expression, cardiomyocyte hypertrophy, and graft fibrosis.  This prompted our 
investigation into the role of IL-6 in the initiation of hypertrophy and fibrosis associated 
with cardiac CR. 
 
Figure 14  Increased intragraft IL-6 expression in grafts undergoing CR. IL-6 message levels in 
cardiac allografts taken from recipients transiently depleted of CD4+ cells (Anti-CD4), recipients 
receiving anti-CD40L mAb therapy (Anti-CD40L), or from syngeneic graft recipients were 
determined at given time points using quantitative real time PCR. Bars represent mean + S.E.M. of 
3–6 grafts per group which were harvested at the given time points. *Day 30 Anti-CD4 vs. Anti-
CD40L, p= 0.0141 and Anti-CD4 vs. Syngeneic, p= 0.0083. ‡ Day 49: Anti-CD4 vs. Anti-CD40L, p= 
0.0150 and Anti-CD4 vs. Syngeneic, p= 0.0102. 
Neutralizing IL-6 reduces cardiac hypertrophy and fibrosis 
To better understand the role of IL-6 in promoting hypertrophy and fibrosis in 
CR, allograft recipients transiently depleted of CD4+ cells were treated with neutralizing 




cardiomyocyte area (p<0.0008) and intragraft ANP transcript levels (p=0.0002) were 
significantly reduced compared to recipients treated with control rat IgG (Figure 10).   
 
Figure 15  Neutralizing IL-6 reduces cardiomyocyte hypertrophy. (A) Representative views of H&E 
stained sections of day 30 post transplant cardiac allografts taken from recipients that were 
transiently depleted of CD4+ cells which also received either control rat IgG (Anti-CD4 + Rat IgG) 
or neutralizing IL-6 mAb (Anti-CD4 + Anti-IL-6). Arrows highlight representative cardiomyocytes. 
(B) Cardiomyocyte area quantitation of groups described in (A). Bars represent mean + S.E.M. of 
area measurements taken from >80 cardiomyocytes per heart in each of 5 different grafts per group. 
(C) Intragraft atrial natriuretic peptide (ANP) message levels in grafts described in (A) were 
determined using quantitative real time PCR. Bars represent mean + S.E.M. of tissue harvested from 
at least 5 different transplants per group. 
Decreases in these parameters implicate IL-6 induces cardiac hypertrophy and 
demonstrate that its neutralization can ameliorate cardiac hypertrophy associated with 
CR.  Furthermore, IL-6 neutralization reduced graft fibrotic tissue area (p<0.0001, Figure 






Figure 16  Neutralizing IL-6 reduces cardiac fibrosis. (A) Representative views of Masson's 
trichrome staining of day 30 post transplant cardiac allografts taken from recipients transiently 
depleted of CD4+ cells which also received either control rat IgG antibodies (Anti-CD4 + Rat IgG) or 
neutralizing IL-6 mAb (Anti-CD4 + Anti-IL-6). (B) Morphometric analysis of graft fibrosis in groups 
described in (A). Bars represent the combined mean + S.E.M. of fibrotic (blue) area from at least 10 
different frames of view from each of at least 6 different cardiac grafts. (C) Intragraft collagen αI 
message levels in cardiac allografts taken from recipients described in (B) were determined using 
quantitative real time PCR. Bars represent mean + S.E.M. of tissue harvested from at least 6 
different transplants per group. 
Neutralizing IL-6 normalizes graft functional parameters 
Since neutralizing IL-6 ameliorated both hypertrophy and fibrosis as determined 
by histologic and gene expression analyses, we assessed the effects of anti-IL-6 on 
anatomical and functional parameters of chronically rejecting hearts.  Echocardiography 
revealed that neutralizing IL-6 prevented the increase in PWT and normalized FS and 





Figure 17  Neutralizing IL-6 ameliorates contractile parameter aberrations associated with CR. 
Serial echocardiography was used to monitor anatomical and functional parameters in cardiac 
allograft recipients that were transiently depleted of CD4+ cells which also received neutralizing IL-6 
mAb (Anti-CD4 + Anti-IL-6, circles). Results are plotted against 3 recipients that were transiently 
depleted of CD4+ cells (Anti-CD4, squares) from Figure 2. Echocardiographic parameters included 
posterior wall thickness (PWT) (A), fractional shortening (FS) (B), and left ventricle ejection fraction 
(LVEF) (C). For the anti-IL-6 mAb treated group, 5 transplants were followed throughout the 
duration of the experiment. Individual points represent mean and bars represent ± S.E.M. of grafts 
analyzed at the given time point. 
Thus, hypertrophy, fibrosis and subsequent deterioration of graft contractility were 
ameliorated in grafts whose recipients were treated with anti-IL-6 mAb.  These are the 
first data to demonstrate that IL-6 may provide a therapeutic target for preventing CR. 
IL-6 neutralization does not inhibit CD4+ cell repopulation of the 
periphery   
In this model of CR, CD4+ cells begin to repopulate the periphery between 3 and 




CD4+ cell repopulation, flow cytometry was performed on splenocytes taken from 
animals receiving anti-IL-6 mAb or control rat IgG.  Both treatment groups had similar 
percentages of CD4+ cells on day 30 or day 50 post transplant (Figure 14), indicating that 
neutralizing IL-6 does not prevent CD4+ cell repopulation of the periphery. 
 
Figure 18  Neutralizing IL-6 does not prevent CD4+ cell repopulation in cardiac allograft recipients. 
Flow cytometric analysis was performed on splenocytes harvested from naïve mice or allograft 
recipients that were transiently depleted of CD4+ cells which also received either control rat IgG 
antibodies (Anti-CD4 + Rat IgG) or neutralizing IL-6 mAb (Anti-CD4 + Anti-IL-6). Splenocytes were 
harvested from cardiac allograft recipients on day 30 (triangles) or day 50 (circles) post transplant. 
Lines represent group mean, n.s. = not significant. 
Elevated intragraft TGFβ, IL-6, and CTGF expression correlate with 
CR 
 Transduction of allografts, but not syngeneic grafts, with TGFβ is sufficient to 
induce CTGF and CR (236), indicating the involvement of an immune component in 
TGFβ-mediated fibrosis.  This is further supported by the identification of IL-6 as a 





Figure 19  Elevated intragraft expression of TGFβ, IL-6, and CTGF in cardiac allografts undergoing 
CR. TGFβ, IL-6, and CTGF message levels were determined at day 30 post transplant using 
quantitative real time PCR in syngeneic cardiac grafts, cardiac allografts from recipients treated 
with anti-CD40L mAb therapy (Anti-CD40L), or cardiac allografts whose recipients were transiently 
depleted of CD4+ cells (Anti-CD4).  Bars represent mean + S.E.M. of 4-9 grafts with expression 
relative to GAPDH normalized to the syngeneic group. 
Hence, the in vivo interactions of TGFβ, CTGF, and IL-6 in CR were the focus of this 
study.  TGFβ, CTGF, and IL-6 transcripts were measured in grafts whose recipients were 
transiently depleted of CD4+ cells, which develop CR, and compared to allografts whose 
recipients were treated with anti-CD40L, which do not develop CR, or untreated 
syngeneic grafts.  Intragraft levels of TGFβ, IL-6, and CTGF were significantly increased 
(p=0.0476, p=0.0254, and p=0.0079 respectively) in cardiac allografts whose recipients 
were transiently depleted of CD4+ cells than in grafts whose recipients were treated with 
anti-CD40L or syngeneic controls (Figure 15).  Thus, the upregulation of all three 
cytokines was observed in grafts undergoing CR.  
Forced expression of CTGF or TGFβ promotes allograft fibrosis 
 To determine whether exogenous expression of CTGF promotes cardiac fibrosis, 
allografts and syngeneic grafts were transduced with AdCTGF.  AdCTGF transduction of 




area by day 30 post transplant compared to allografts with control virus (Figure 15A).  
 
Figure 20  Forced expression of TGFβ or CTGF promotes allograft fibrosis.  (A)  Morphometric 
analysis of Masson’s trichrome staining at day 30 post transplant in cardiac grafts that were left 
untransduced or transduced with adenoviral vectors encoding βgal (Adβgal), CTGF (AdCTGF), or 
TGFβ (AdTGFβ) prior to grafting into syngeneic recipients or allogeneic recipients treated with anti-
CD40L.  Bars represent the combined mean + S.E.M. of fibrotic (blue) area of 10-12 frames of view 
per heart taken from 5 to 12 different cardiac grafts per group. (B)  Intragraft IL-6 message levels 
were determined at day 30 post transplant using quantitative real time PCR in groups from (A).  
Bars represent mean + S.E.M. of at least 4 hearts per group with expression relative to GAPDH 
normalized to naïve, untransplanted BALB/c hearts.  (C)  Intragraft IL-17 message levels were 
determined using quantitative real time PCR in syngeneic grafts transduced with AdTGFβ or 
allogeneic grafts transduced with AdTGFβ whose recipients received anti-CD40L treatment.  Bars 
represent mean + S.E.M. of at least 5 independent hearts per group with expression relative to 
GAPDH normalized to the naïve BALB/c group. 
In contrast, syngeneic grafts transduced with AdCTGF had similar levels of fibrosis to 
controls.  It should be noted that the mean fibrotic area for AdCTGF-transduced 
allografts was less than in hearts transduced with AdTGFβ, consistent with previous 
descriptions in lung transductions (283).  This difference could not be accounted for by 




comparable in these studies as determined by real time PCR (Appendix 2).  Thus, while 
forced expression of either TGFβ or CTGF promoted cardiac allograft fibrosis, they did 
so to different extents (Figure  15)  This could in part be due to TGFβ induction of 
endogenous CTGF expression (236, 252, 284), thereby producing an additive effect.   
 It has been observed that TGFβ and CTGF are potently fibrotic in tandem while 
less fibrotic individually (285, 286).  Therefore, we asked whether co-transduction of 
both TGFβ and CTGF vectors would induce fibrosis and CR in syngeneic grafts.  No 
increases in fibrosis were observed upon co-transduction of syngeneic grafts compared to 
single virus transduction (Appendix 3).  Thus, while injection of TGFβ and CTGF 
synergize to cause fibrotic responses in the skin (286), forced expression of both was 
insufficient to induce fibrosis or CR in syngeneic cardiac grafts, further supporting the 
requirement of an immune component.   
We next considered whether the greater fibrotic activity of AdTGFβ relative to 
AdCTGF could be due to immunologic effects.  TGFβ is chemotactic for multiple 
immune cell types (238) that are able to produce IL-6, which we have recently reported to 
play a critical role in CR (265).  Therefore we asked whether differences in intragraft IL-
6 expression might account for these disparate outcomes.  IL-6 transcript levels exhibited 
a suggested increase in AdTGFβ, but not AdCTGF transduced allografts whose recipients 
received anti-CD40L therapy.  No increases in IL-6 expression were observed in 
AdTGFβ or AdCTGF-transduced syngeneic grafts (Figure 15B).   
TGFβ and IL-6 have been implicated in the development of Th17 responses 




expression of IL-17 in allogeneic and syngeneic grafts transduced with AdTGFβ.  IL-17 
expression was significantly greater (p=0.0107) in allografts than in syngeneic grafts 
(Figure 15C) while IL-17 expression was similar in allogeneic and syngeneic grafts 
transduced with AdCTGF.  Thus, increased IL-17 and CTGF transcript levels may 
promote fibrosis associated with AdTGFβ-transduced allografts, but not AdTGFβ-
transduced syngeneic grafts that do not develop fibrosis. 
IL-6 neutralization reduces intragraft CTGF and IL-17 transcripts 
 The association between TGFβ, IL-6, and CTGF (Figure 15) may be strengthened 
by previous reports that IL-6 enhances TGFβ signaling by altering receptor localization in 
the cell membrane (263) and that IL-6 can alter the outcome of TGFβ signaling (261, 
262).  Indeed, we have previously reported that IL-6 neutralization prevents CR of 
cardiac allografts (265).  We therefore asked whether IL-6 neutralization would inhibit 





Figure 21  IL-6 neutralization reduces expression of IL-6, IL-17, and CTGF but not TGFβ in cardiac 
allografts undergoing CR.  Intragraft IL-6, IL-17, CTGF, and TGFβ message levels were determined 
at day 30 post transplant using quantitative real time PCR in cardiac allograft recipients that were 
transiently depleted of CD4+ cells and received either neutralizing anti-IL-6 (Anti-IL-6) or control 
rat IgG (rIgG).  Bars represent mean + S.E.M. of 6-8 grafts per group with expression relative to 
GAPDH normalized against rIgG-treated contols. 
In allografts whose recipients were transiently depleted of  CD4+ cells, treatment with 
anti-IL-6 mAb significantly reduced intragraft IL-6, IL-17, and CTGF expression 
(p=0.0216, p=0.0044, and p=0.0180 respectively) compared to control antibody 
treatment.  In contrast, TGFβ expression levels remained unchanged (Figure 16).  Thus, 
IL-6 promotes intragraft IL-6, IL-17, and CTGF expression. 
CTGF neutralization ameliorates allograft fibrosis 
 To determine if CTGF neutralization would inhibit the fibrosis associated with 




neutralizing anti-CTGF mAb or control antibody.  Anti-CTGF mAb significantly reduced 
fibrotic area (p<0.0001, Figures 17A and B), but not intragraft TGFβ, CTGF, or IL-6 
transcripts (Figure 17C).  These observations support a role for CTGF as a downstream 
mediator of fibrosis associated with CR.  
 
Figure 22  CTGF neutralization ameliorates fibrosis.  (A) Representative sections of Masson’s 
trichrome stains, in which fibrotic tissue stains blue, of cardiac allografts from recipients transiently 
depleted of CD4+ cells (Anti-CD4) at day 30 post transplant in recipients treated with control IgG or 
neutralizing anti-CTGF mAb (200X magnification).  (B) Morphometric analysis of trichrome 
staining of groups in (A).  Bars represent mean + S.E.M. of 10-12 frames of view from each of 6 to 9 
hearts.   (C) TGFβ, IL-6, and CTGF message levels were determined at day 30 post transplant using 
quantitative real time PCR in cardiac allografts described in (A).  Bars represent mean + S.E.M. of 
samples taken from 8-12 different cardiac grafts with expression relative to GAPDH normalized 




CTGF neutralization decreases cardiomyocyte hypertrophy associated 
with CR 
 CTGF can induce cardiomyocyte hypertrophy (289, 290), a function it shares with 
IL-6 (265).  Since IL-6 neutralization inhibited CTGF expression (Figure 16), we 
assessed the effect of neutralizing CTGF on cardiomyocyte hypertrophy.  Anti-CTGF 
treatment significantly decreased (p<0.0001) cardiomyocyte hypertrophy (Figure 18A) 
and (p=0.0102) intragraft expression of ANP (Figure 18B), a molecular marker of cardiac 
hypertrophy (279, 280).  For reference, cardiomyocyte area and ANP expression levels 
for naïve, untransplanted BALB/c hearts and allografts transplanted into recipients 






Figure 23  CTGF neutralization ameliorates cardiac hypertrophy in CR grafts.  (A) Cardiomyocyte 
area was quantified from H&E stains of day 30 post transplant cardiac allografts taken from 
recipients transiently depleted of CD4+ cells (Anti-CD4) and receiving CTGF neutralizing mAb 
(Anti-CTGF) or control antibodies (hIgG), recipients treated with Anti-CD40L mAb, or naïve, 
untransplanted BALB/c hearts.  Bars represent mean + S.E.M. of area measurements taken from 
≥100 cardiomyocytes per heart from 5 (naïve BALB/c and Anti-CD40L), 8 (Anti-CD4+hIgG), or 10 
(Anti-CD4+Anti-CTGF) different hearts per group.  (B) Intragraft message levels of atrial 
natriuretic peptide (ANP), a marker of cardiac hypertrophy, were quantified with real time PCR in 
cardiac grafts from groups in (A) at day 30 post transplant.  Bars represent mean + S.E.M. of 8-12 
grafts per experimental group (Anti-CD4+hIgG or Anti-CTGF) and 4 grafts per control group (Anti-
CD40L and naïve BALB/c) with expression relative to GAPDH normalized against the naïve BALB/c 
hearts. 
 
CTGF neutralization inhibits T cell infiltration of grafts 
 CTGF promotes integrin-mediated adhesive responses in multiple cell types (291-
300) and induces the production of chemokines (301).  We therefore asked whether 
CTGF neutralization might also alter the infiltration of immune cells into grafts 




receiving anti-CTGF (Figure 19A).  Indeed, a significant decrease (p=0.0238) in TCRβ 
constant region expression, a marker of graft infiltrating T cells (302), was observed 
(Figure 19B).   
 
Figure 24  CTGF neutralization limits graft infiltration by T cells in CR grafts.  (A)  Representative 
H&E stains of day 30 post transplant cardiac allografts taken from recipients transiently depleted of 
CD4+ cells (Anti-CD4) and receiving CTGF neutralizing mAb (Anti-CTGF) or control antibodies 
(hIgG).  Stains suggest a reduction in perivascular infiltrate density in grafts treated with 
neutralizing Anti-CTGF.  (B)  Intragraft message levels of T cell receptor β constant region (TCRβ) 
were quantified at day 30 post transplant with real time PCR as a measure of T cell infiltration of 
allografts in recipients transiently depleted of CD4+ cells (Anti-CD4) and receiving anti-CTGF mAb 
or control hIgG antibodies, recipients treated with Anti-CD40L mAb, or naïve BALB/c hearts.  Bars 
represent mean + S.E.M. of 8-12 grafts per group with expression relative to GAPDH normalized 
against the hIgG group.  (C)  Repopulation of CD4+ cells in the periphery at day 30 post transplant 
was determined by flow cytometric analysis of splenocytes isolated from graft recipients.  Bars 
represent mean + S.E.M. of the percentage CD4+ cells of the gated cell population in 5 to 7 recipients 
tested. 
To verify that this difference was not due to CTGF neutralization preventing peripheral 




and control treated graft recipients.  No significant differences were observed between 






CR is characterized by the formation of patchy interstitial fibrosis and occlusion 
of vascular structures accompanied by progressive graft dysfunction (105, 303).  
Currently, there is no therapeutic which specifically targets CR.  Although several factors 
have been implicated in CR, the etiology and changes associated with the progression of 
the disease are not fully understood.  To better define these changes we monitored the 
progress of CR using echocardiography.   
Echocardiography has been demonstrated to be effective for monitoring acute 
rejection (269) and long term acceptance (304) of heterotopic mouse cardiac grafts.  We 
used echocardiography to successfully monitor the progression of CR in mice.  Further, 
we have identified critical elements of the disease process, notably that the fibrosis of CR 
is associated with cardiac hypertrophy and that both processes are driven by IL-6.   
Grafts undergoing CR had increased PWT, a reproducible measure of cardiac 
rejection in mice (269).  Such increases in PWT could be caused by immunologic and 
inflammatory processes associated with CR such as edema, graft-infiltrating cells, cell 
proliferation and collagen deposition (105, 303).   However, echocardiographic 
functional analyses (FS and LVEF) revealed increased graft contraction coincident with 
increased PWT by day 35 post transplant in CR grafts (Figure 7).  Together, these 




undergoing CR.  Manifestations of hypertrophy were followed by significant 
deterioration of graft contractility by day 42 post transplant.  Such declines in cardiac 
contractility mirror events observed in human heart failure (306).  These observations 
implied that day 30 post transplant represents a critical time point of CR in this mouse 
model as it exhibits near terminal amounts of interstitial fibrosis (Figure 6) and increases 
in functional parameters indicative of hypertrophy (Figure 7).    
Hypertrophy in CR grafts was confirmed by increased cardiomyocyte area (Figure 
8B) and elevated levels of ANP (Figure 8C), a marker whose up-regulation has been 
linked to cardiac hypertrophy in multiple models (279, 280).  Although cardiomyocyte 
hypertrophy has been reported in other models of cardiac failure (307-309), our data 
suggest a concomitance of cardiac hypertrophy with CR.  Since it is widely accepted that 
immunologic factors contribute to CR, we considered that an immunologic factor might 
be promoting hypertrophy (281).  Indeed, it has been demonstrated that increased IL-6 
signaling is sufficient to induce cardiac hypertrophy and ventricular wall thickening in 
vivo (310).  It should be noted that while sufficient to induce cardiac hypertrophy, IL-6 is 
dispensable for adaptive physiologic hypertrophy responses to exercise training (311, 
312).  Thus, while unnecessary for physiologic hypertrophy, IL-6 has been implicated in 
pathological cardiac hypertrophy in humans (313, 314) and animals (280, 315-317).   
Elevated intragraft IL-6 transcript levels at day 30 post transplant coincided with 
graft hypertrophy and fibrosis in grafts undergoing CR (Figures 6, 7, 9, and 14).  It is of 
note that significant elevation of IL-6 expression in allografts undergoing CR at days 30 




(Figure 9).  The importance of this early peak in the bimodal expression of IL-6 is 
unclear, though it is not likely due to ischemic/reperfusion injury in that syngeneic 
control grafts did not exhibit a similar early elevation of IL-6.  One possibility is that the 
early elevation of IL-6 expression in allograft recipients treated with anti-CD4 mAb may 
be associated with the process of depleting CD4+ cells. 
IL-6 has previously been suggested as a therapeutic target for hypertrophy (318), 
therefore, we neutralized IL-6 to assess its role in the hypertrophy associated with CR.  
Neutralizing IL-6 reduced cardiomyocyte area (Figure 10) and prevented the increases in 
PWT, FS and LVEF indicative of cardiac hypertrophy that were observed in CR grafts 
(Figure 13).  These results implicate IL-6 as an inducer of hypertrophy in CR.  Further, 
targeting IL-6 may ameliorate hypertrophy while stabilizing functional parameters in 
cardiac allografts undergoing CR.   
Neutralizing IL-6 not only decreased cardiomyocyte hypertrophy but also 
lessened fibrosis of the graft (Figure 13).  This finding is consistent with previous in vitro 
studies in which IL-6 increased collagen transcript levels in co-cultures of cardiac 
fibroblasts and cardiac myocytes (282) and treatment with IL-6 neutralizing mAb 
decreased cardiac fibroblast proliferation (319).  Further, IL-6 may induce factors that 
facilitate fibroblast survival (320).  Thus, decreased survival, proliferation, and collagen 
αI transcript levels in cardiac fibroblasts may explain the anti-fibrotic effects of 
neutralizing IL-6 in our study. 
Beyond its roles in hypertrophy and fibrosis, IL-6 is also a potent modulator of 




(reviewed in (321-323)).  Hence, it is possible that IL-6 neutralization ameliorates CR in 
this model through immunomodulatory effects.  IL-6 neutralization could prolong graft 
survival by impairing the transition of graft-reactive immunity from innate responses to 
adaptive responses, perhaps through disruption of the neutrophil to monocyte recruitment 
progression (321).  Additionally, lymphocyte homing to the graft may be impaired, as IL-
6 can induce the expression of monocyte chemotactic protein 1 in fibroblasts (324) as 
well as promote T cell migration on fibronectin substrate (325).  In addition to promoting 
recruitment, IL-6 can rescue T cells from apoptosis (326).  It is therefore conceivable that 
neutralizing IL-6 could further enhance graft survival through both failure to recruit and 
increased apoptosis of graft-reactive T cells.   
Neutralizing IL-6 does not inhibit CD4+ cell repopulation in this system (Figure 
14).  Therefore, we asked whether neutralizing IL-6 had other effects on CD4+ or CD8+ 
cell function.  To this end, ELISPOT assays (21) were performed on splenocytes 
harvested on day 30 post transplant from allograft recipients that were initially depleted 
of CD4+ cells and treated with either anti-IL-6 mAb or rat IgG.  ELISPOT assays for 
donor-reactive IFN-γ, IL-4, and IL-17 producing cells were performed on whole 
splenocytes, splenocytes depleted of CD4+ cells, and splenocytes depleted of CD8+ cells.  
Similarly low frequencies (<50 spots/million cells) of donor-reactive cytokine producing 
cells were present in the spleens of rat IgG or anti-IL-6 treated recipients, indicating that 
IL-6 neutralization did not alter the immune response at the level of Th subset function.  
Hence, both CD4+ and CD8+ Th1, Th2, and Th17 remained hyporesponsive in the 




IL-6 can augment antigen-specific antibody responses in mice (327), therefore we 
assessed serum levels of donor-reactive IgM or IgG.  No significant difference was 
observed between anti-IL-6 treated recipients or controls (Appendix 4).  It should be 
noted that these observations do not rule out other immunomodulatory effects of IL-6 
neutralization in this setting.  Indeed, anti-IL-6 mAb might alter lymphocyte trafficking 
to the graft (324, 325, 328), lymphocyte survival (326), activation and differentiation 
(261), as well as the immunologic events initiating fibrosis.  
It has been demonstrated in vitro that hypertrophic stimuli such as IL-6 can 
induce cardiac myocyte production of factors known to promote fibrosis, including 
CTGF (290) and TGFβ (329).  We have previously reported a strong correlation between 
intragraft expression of TGFβ and CTGF with CR (236).  This indicated that IL-6 might 
induce similar pro-fibrotic gene expression in vivo.  It should be noted that in addition to 
potential enhancement of TGFβ production through the induction of hypertrophy, IL-6 
may also directly augment TGFβ signaling by regulating turnover and 
compartmentalization of its receptor (263).  Furthermore, it has recently been reported 
that the C-terminal domain of CTGF can induce cardiomyocyte hypertrophy (289).  
Together, these data suggest that IL-6 may be a promoter of multiple factors able to 
promote both hypertrophy and fibrosis in CR.   
The elucidation of a critical role for IL-6 in CR led us to evaluate of the 
associations of IL-6 with other factors associated with CR, especially TGFβ (237).  The 
role of TGFβ in CR is complicated by its pleiotropic activity encompassing 




immune (250, 333) cells as well as the induction of Treg (334-336), which are associated 
with graft acceptance (247, 248, 259).  Thus, TGFβ may promote graft survival and 
global immune tolerance while suppressing malignancy, making it ill-suited as a 
therapeutic target in the treatment of CR.  This has prompted investigation into the 
downstream mediators of fibrotic TGFβ function (100, 236).  
Multiple reports indicate that TGFβ requires additional factors to drive fibrosis 
(236, 285, 286).  Indeed, syngeneic grafts do not develop fibrosis in response to TGFβ, 
while allografts whose recipients receive anti-CD40L mAb develop marked fibrosis in 
response to TGFβ (Figure 15, (236)).  Hence, alloimmune responses potentiate the pro-
fibrotic effects of TGFβ.  We considered that IL-6 may be the immune factor that 
potentiates TGFβ actions in CR (265).  Indeed, elevated IL-6 expression correlated with 
TGFβ and CTGF (Figure 15).  Correlations of TGFβ with CTGF (236) and TGFβ with 
IL-6 (265) have previously been described.  Further, we have previously observed CTGF 
expression associated with areas of graft-infiltrating mononuclear cells (236), whose 
recruitment during inflammatory responses has been linked to IL-6 (337, 338).  
Therefore, we considered that there may be connectivity between all three cytokines.   
To ascertain the sufficiency of TGFβ and CTGF to induce CR, allogeneic and 
syngeneic cardiac grafts were transduced with AdTGFβ or AdCTGF and transplanted 
into recipients receiving anti-CD40L mAb or syngeneic recipients.  AdTGFβ and 
AdCTGF significantly increased mean fibrotic area compared to untransduced or control 
vector treated allografts (Figure 15A).  Consistent with a previous report of adenoviral 




significantly greater than the response to CTGF transduction (Figure 15A).  Greater 
fibrotic responses to AdTGFβ could be from synergy of TGFβ-induced immune factors 
and CTGF in cardiac allografts, an effect which is not observed in syngeneic grafts (236).  
Further, in cardiac allografts, TGFβ induction of endogenous CTGF may synergize with 
TGFβ-mediated chemotactic effects on multiple immune lineage cells (238), which may 
explain the suggested upregulation of IL-6 and significant upregulation of IL-17 (Figure 
15).     
Given the differences in AdTGFβ responses between allografts and syngeneic 
grafts (Figure 15) and the correlation of TGFβ and CTGF with IL-6 in CR (Figure 15), 
we asked whether the presence of IL-6 was required for CTGF upregulation.  In cardiac 
allograft recipients transiently depleted of CD4+ cells, IL-6 neutralization reduced the 
expression of IL-6 and CTGF without altering TGFβ transcript levels (Figure 16).  This 
suggests that TGFβ transcript regulation lies upstream of IL-6 and CTGF in CR.  It 
should be noted that IL-6 neutralization does not prevent repopulation of CD4+ cells in 
the periphery (Figure 14, (265)).  This indicates that the ability of IL-6 neutralization to 
prevent CR (265) could function in part through reduction of intragraft CTGF.   
Another explanation of the efficacy of IL-6 neutralization could be effects in T 
cell lineage decisions.  It is known that the presence or absence of IL-6 may determine T 
cell responses to TGFβ, as TGFβ and IL-6 result in sTh17 effector cells while TGFβ 
without IL-6 can generate FoxP3+ regulatory cells (261).  The possibility that this axis of 
effector/regulatory T cell responses may be a key factor in CR is supported by historic 




human cardiac allografts (302).  Furthermore, a role for IL-17 in the pathology of CR 
seems more likely in light of observations that IL-17 alone stimulates increased collagen 
production in primary mouse cardiac fibroblasts (339).  This is consistent with a report 
that Th17 responses to collagen type V correlate with the development of bronchiolitis 
obliterans syndrome in lung transplant patients (287) and that IL-17 has recently been 
associated with the development of CAV (288).  In these studies IL-6 neutralization 
significantly inhibited IL-17 expression (Figure 16), indicating that IL-17 might play a 
role in CR possibly through CTGF induction, as IL-17 has been reported to induce 
collagen production in cardiac fibroblasts (339).  Another explanation for this effect 
might be decreased recruitment of graft infiltrating cells which may express or induce 
local cells to express CTGF (236), IL-6 and IL-17.  Indeed, IL-6 induces chemotaxis and 
migration of immune cells (321, 325).   
Since IL-6 neutralization ameliorated CR (Figures 10-12, (265)) and decreased 
intragraft CTGF expression (Figure 16), we treated cardiac allograft recipients with 
neutralizing CTGF mAb.  CTGF neutralization significantly reduced allograft fibrosis 
(Figures 17A, B) without significantly reducing intragraft TGFβ, IL-6, or CTGF 
expression (Figure 17C).  These findings are consistent with CTGF being a downstream 
mediator of fibrosis in CR (100, 251, 283, 340). 
The significant but incomplete reduction in fibrotic area in response to CTGF 
neutralization may be explained by multiple factors.  Our neutralization protocol, though 
effective, may not be optimal.  Another possibility is the presence of CTGF-independent 




mAb FG-3019, which recognizes CTGF module 2 in humans and rodents (268), might 
inhibit some but not all pro-fibrotic effects of CTGF.  However, this possibility seems 
unlikely in light of a recent report evaluating the anti-fibrotic efficacy of anti-CTGF 
antibodies directed against each of the four CTGF modules.  In this report, only mAb 
directed against the von Willebrand factor type C domain (module 2) was able to inhibit 
TGFβ-induced fibrosis (342).  Indeed, this is the same domain that the anti-CTGF mAb 
utilized in our study binds (267, 268). 
Beyond its roles in fibrosis, CTGF can exert other effects relevant to CR.  Recent 
studies have described a concomitance of cardiomyocyte hypertrophy with CR in humans 
(265, 343, 344).  CTGF is produced by hypertrophic chondrocytes during development 
(345), and is produced by cardiac myocytes in response to hypertrophic stimuli (290).  In 
addition, CTGF itself can induce cardiomyocyte hypertrophy (289).  Treatment with 
neutralizing anti-CTGF mAb significantly reduced mean cardiomyocyte area (Figure 
18A) and intragraft levels of ANP (Figure 18B), a marker of cardiac hypertrophy in 
multiple settings (265, 279, 280).  However, it should be noted that anti-CTGF mAb did 
not inhibit cardiac hypertrophy to the extent observed with anti-IL-6 (265).  This finding 
indicates that in addition to driving cardiac fibrosis, CTGF may augment cardiomyocyte 
hypertrophy associated with CR.  Interestingly, hypertrophy is associated with 
downregulation of two recently discovered CTGF-inhibiting micro RNAs in cardiac 
myocytes (346).  Thus, CTGF may be linked to cardiac hypertrophy on multiple levels. 
Finally, as CTGF is known to play an important role in fibroblast adhesion in 




recruitment of lymphocytes to the graft.  Histologic assessment of infiltrating cells was 
indicative of reduced numbers of graft infiltrating lymphocytes (Figure 19A).  This 
observation was further supported by significant reduction of intragraft TCRβ constant 
region expression (Figure 19B) in response to CTGF neutralization.   
Based on these observations and others in the literature, we propose a model 
representing the interactions of TGFβ, IL-6, and CTGF and their induction of 
hypertrophy and fibrosis associated with CR (Figure 20A).   
 
Figure 25  Proposed model of cytokine interactions in chronic rejection.  (A)  In cardiac allografts, 
TGFβ and IL-6 contribute to CTGF production.  IL-6 and CTGF are both known to promote 
hypertrophy in cardiac myocytes, which in turn can produce CTGF.  CTGF functions as a 
downstream mediator of fibrosis.  (B)  Induction of CTGF downstream of TGFβ and IL-6 could be 
explained by the respective presence of a consensus SMAD binding element and a STAT3 response 
element in 5’ region upstream of the CTGF promoter.  For expanded explanations, please see text. 
In cardiac allografts that undergo CR, TGFβ (Figure 15, (236)) and IL-6 (Figures 9, 15, 
and 16B, (265)) are induced.  In syngeneic grafts, forced expression of TGFβ is 
insufficient to upregulate CTGF and fibrosis (236), and IL-6 remains at basal levels 
(Figure 16B).  IL-6 neutralization inhibits hypertrophy and fibrosis associated with CR 




TGFβ expression remains unchanged (Figure 16).  Thus, TGFβ and IL-6 appear to be 
upstream promoters of CTGF expression and CR.  CTGF neutralization limits fibrosis 
(Figures 17A, B) and decreases cardiomyocyte hypertrophy (Figure 18), without altering 
intragraft TGFβ, IL-6, or CTGF transcripts (Figure 17C).  These effects of CTGF 
neutralization coincide with reduction in graft infiltrating T cells (Figure 19).  Together, 
these observations support a downstream role for CTGF in fibrosis and hypertrophy.   
Contexts in which TGFβ and IL-6 are present coincide with intragraft IL-17 
expression, which has been implicated in promoting cardiac remodeling (347), fibrosis 
(339), bronchiolitis obliterans syndrome in lung transplant patients (287), and cardiac 
allograft vasculopathy (288).  However, the effects of IL-17 on hypertrophy and CTGF 
expression are unclear and merit further investigation.  Our proposed model of CTGF 
induction downstream of IL-6 and TGFβ (and perhaps IL-17) might be explained by 
previous identification of both a STAT3 responsive element (–740 to –736 bp) (348) and 
a consensus SMAD binding element (-173 and -166 bp) (349) upstream of the CTGF 
promoter (Figure 20B).  Hence, optimal induction of CTGF in CR may require that 
CTGF producing cells receive both SMAD and STAT3 signals, likely provided by TGFβ 
(238) and IL-6 (350) respectively. 
These studies support the use of echocardiography for monitoring the in vivo 
changes occurring in CR, which helped identify a previously unrecognized immunologic 
axis in the development of chronic cardiac allograft rejection.  These echocardiographic, 
histologic, and molecular findings suggest a critical role of IL-6 in the cardiac 




IL-6 neutralization may represent the first therapeutic approach to ameliorate hypertrophy 
and fibrosis associated with CR while stabilizing anatomical and functional parameters of 
the graft.  These investigations also support a role for CTGF as a downstream mediator of 
fibrosis and highlight the essential contributions of immune elements to CR and fibrosis 
of cardiac grafts while elucidating relationships between TGFβ, IL-6, and CTGF.  
Further, these studies indicate for the first time that mAb neutralizing CTGF can 
ameliorate fibrosis and hypertrophy associated with CR.  These findings further implicate 
IL-6 as a critical immune factor in CR that may potentiate TGFβ-mediated CTGF 
induction.  Finally, TGFβ-mediated induction of fibrosis in allogeneic but not syngeneic 
grafts was associated with a suggested increase in intragraft IL-6 expression and a 
significant increase in IL-17 expression, supporting the notion that TGFβ induction of 







 CR of transplanted organs remains the most significant barrier to both the long 
term survival of transplanted organs as well as the effective use of transplantation in the 
clinic.  There is currently no effective treatment that targets CR, with the best hope being 
prevention through strong immunosuppression, which may spare the graft while it 
subverts long term survival of the graft recipient through increased tumorigenesis and 
opportunistic infections.  These investigations have endeavored to better understand the 
physiologic and molecular etiology of CR in cardiac allografts and have tested two 
therapeutic approaches for CR.  Through echocardiographic investigations described here 
and similar concurrent observations in the clinic, it has become apparent that pathologic 
cardiomyocyte hypertrophy is a defining physiologic feature of CR in cardiac allografts.  
Further, these investigations identified a critical role for IL-6 in the initiation of cardiac 
hypertrophy associated with CR.  In addition to promoting pathologic hypertrophy 
associated with CR, IL-6 is an upstream promoter of CTGF and CTGF is a downstream 
mediator of fibrosis in CR. 
 These investigations in cardiac grafts have centered on hypertrophy as a signature 
of pathologic events occurring within the graft.  However, cardiac hypertrophy is 




factors defining physiologic versus pathologic hypertrophy has been the source of intense 
investigations.  Some signaling elements (351) as well as the differentiation state of 
cardiac fibroblasts (352) were previously known to distinguish between physiologic and 
pathologic hypertrophy.  These findings, namely the critical role of IL-6 in the induction 
of pathologic transplant cardiac hypertrophy, illustrate the complex and wide reaching 
effects of immune responses to the graft—even graft physiology. 
 The identification of IL-6 as a critical mediator of CR greatly informed previous 
experimental observations about the role of initiating immune factors in CR.  Cardiac 
allografts administered anti-CD40L therapy and transduced to express TGFβ developed 
CR, whereas similarly transduced syngeneic grafts did not (Figure 16).  Though it was 
clear that immune-mediated factors were responsible for the differences in these 
outcomes, the necessary immune factors were not known.  These investigations indicate 
that IL-6 is a critical mediator of TGFβ actions in CR, potentially through the induction 
of anti-graft IL-17 responses (Figure 16C).  These studies further indicate that the 
immune factors TGFβ and IL-6 induce the production of CTGF, possibly through 
induction of IL-17.  It should be noted, however that the presence of SMAD and STAT 
response elements upstream of the CTGF promoter suggest that the induction of IL-17 
may not be necessary for CTGF induction.   
Investigations utilizing CTGF neutralization indicate that CTGF functions 
downstream of TGFβ and IL-6 as a true downstream mediator of fibrosis.  Though CTGF 
neutralization did not completely abrogate fibrosis in the CR model assessed, it did 




unclear.  CTGF neutralization did not significantly reduce expression of type I collagen, 
perhaps indicating that CTGF promotes accumulation of fibrotic tissue in CR of cardiac 
allografts on a post translational level.    
Implication of Findings 
These studies were undertaken in large part to understand the etiology of CR, a 
debilitating disease that will at some point affect most patients receiving a solid organ 
transplant.  It is therefore worthwhile to consider the prospective applications of these 
findings clinically.  The potential clinical relevance of these echocardiographic studies is 
highlighted by a recent report in which echocardiography defined cardiac allograft 
hypertrophy as a prognostic marker for the development of allograft vasculopathy and 
increased patient mortality (343).  As pointed out in an accompanying Editorial (344), 
cardiac allograft hypertrophy and its association with graft vasculopathy may provide a 
surrogate marker for patient survival in clinical cardiac transplantation.  Hence, 
echocardiography represents a non-invasive technique for assessment of the progression 
of CR.  Importantly, an advantage of echocardiography for detection of CR is that it does 
not suffer the conundrum of judging the entire graft by a small piece, as with transvenous 
endomyocardial biopsy. 
These findings further indicate that IL-6 may be the causative agent for transplant 
associated hypertrophy, recently found to correlate with poor prognosis in transplant 
patients.  Therefore, assessment of IL-6 levels in transplant biopsies or patient serum 
might provide a biomarker to supplement echocardiographic assessment of cardiac 




effective in treating rheumatoid arthritis in the clinic (353).  Actemra was approved for 
the treatment of rheumatoid arthritis in the European Union and Japan in January 2009 
and may soon be approved for treating patients in the United States.  Thus, it appears that 
IL-6 neutralization could provide an alternate or supplementary immunotherapeutic that 
is more efficacious in preventing or treating CR than current approaches.   
The potential for all immunotherapeutics, such as anti-IL-6 mAb, is hindered by 
the general side effects of immunosuppression.  However, the side effects of global 
immunosuppression may be less present with CTGF neutralizing therapeutics, as no clear 
role for CTGF in the development or maintenance of immune responses is known.  In 
these studies, neutralization of CTGF ameliorated the fibrosis associated with CR.  
Though CTGF neutralization was less potent than IL-6 neutralization in staying the onset 
and progression of CR, it may provide a more targeted therapeutic.  In these studies 
CTGF appeared to decrease the presence of graft infiltrating cells.  However, graft 
infiltrating cells were still present.  Thus, targeting CTGF may provide a therapeutic for 
some aspects of CR pathology without significantly augmenting the 
immunocompromised condition of a transplant recipient.  Such a therapeutic would be a 
seemingly excellent compliment to current immunosuppressive regimens used clinically. 
Future Directions 
IL-6 Future Studies 
 These studies have identified several key factors in the initiation and progression 




as well as fibrosis, and a clear definition for CTGF as a downstream mediator of fibrosis 
in CR of cardiac grafts.  Though these findings are important, they delineate the need for 
further investigations.  With respect to the role of IL-6 in the induction and progression of 
CR a number of questions remain.  First, though these investigations clearly illustrate the 
necessity of IL-6 in CR, the cellular and molecular mechanisms by which it contributes to 
CR are not known.  Further investigations should probe the cellular source of IL-6 in CR.  
Multiple cell types are able to produce IL-6 in response to biologic stimuli.  A better 
understanding of which cells are producing IL-6 would not only increase our 
understanding of the biology of IL-6 in CR, but potentially provide inroads for more 
targeted therapeutics.   
Elucidating the cellular source of IL-6 in these models of CR is complicated by 
the ability of IL-6 to signal through both cis and trans mechanisms (Figure 21).  In the 
case of cis signaling, it is expected that IL-6 signaling would only affect cells that express 
the cognate IL-6 receptor α.  IL-6 may also signal to cells that do not express the cognate 
receptor, as IL-6 bound to its cognate receptor α may be proteolytically cleaved from 
multiple cell types, creating an IL-6/IL-6 receptor α complex that can then bind to the 
coreceptor for IL-6 signaling, gp-130.  The gp-130 coreceptor is expressed ubiquitously 
throughout many tissue types and would open up the possibility that the source of IL-6 
signaling in the graft may not be graft cells or graft infiltrating cells, but rather cells in the 
host periphery including the spleen and graft draining lymph nodes.  It should be noted 





Figure 26  IL-6 Signaling and Potential Effects in CR 
 A primary reason for trying to understand the cellular source of IL-6 and the type 
of IL-6 signaling is to elucidate the biology underlying the effectiveness of IL-6 
neutralization in preventing CR.  Knowing the type of IL-6 signaling would facilitate 
further investigations into the cells that respond to IL-6 and what the ultimate effect of 
IL-6 upon these cells in.  In particular it is unclear how IL-6 signaling culminates in CR, 
though several lines of investigation would be appropriate to better understand these 
effects.  These studies indicate that IL-6 neutralization is associated with a decrease in 
intragraft IL-17 expression.  Thus, one possibility is that the effectiveness of IL-6 




more critical molecule.  This theory could be tested through antibody neutralization of 
IL-17 in these models and is currently being explored with IL-17 knockout mice. 
Though there is association of IL-17 in other models of CR, these observations 
may point toward another putative mechanism that IL-6 neutralization works through.  
The pathways of T cell development into inflammatory IL-17 responses or regulatory T 
cell responses have been described as reciprocal.  Current understanding suggests that the 
reciprocity between these two lineages is decided through the absence or presence of IL-6 
or IL-1.  Hence, another effect of IL-6 neutralization might be the developmental 
skewing of graft-reactive cells away from inflammatory lineages toward regulatory cell 
identities.  This hypothesis could be tested both by antigen-specific in vitro suppressor 
assays and by adoptive transfer of sorted cells expressing the FoxP3 transcription factor 
from these transplant recipients into mice that would otherwise reject their grafts.  The 
adoptive transfer approach would have the additional advantage that it would clarify 
whether or not any regulatory cells induced in these mice could have their regulatory cell 
function subverted by an IL-6 competent environment.   
In addition to the potential effects of IL-6 on immune lineage cells, investigations 
probing the effect of IL-6 on non-immune cells including vascular endothelial cells, 
cardiac myocytes, and cardiac fibroblasts should be considered.  IL-6 is one of several 
immune cytokines known to activate vascular endothelial cells, triggering multiple 
responses such as the induction of surface-expressed cellular adhesion molecules that are 
critical for sequestering immune cells to the site of inflammation.  Therefore, it is 




infiltration of immune cells.  Infiltrating cells may then initiate cellular damage, cytokine 
production, and chronic remodeling associated with CR manifesting as CAV and 
interstitial fibrosis.  Infiltrating cells may also have effects upon cardiac myocytes 
through cytokines, as IL-6 is known to induce hypertrophy.  Further, cardiac myocytes 
could be a source of factors that promote fibrotic remodeling associated with CR, 
including TGFβ, CTGF, and even type I collagen.  While cardiac myocytes may produce 
collagen, it is more likely that cardiac fibroblasts produce most collagen in CR of the 
heart.   
The possibility that IL-6 has effects on all three of these cell types may be 
investigated through several approaches.  Since all three of these cell types are graft cells 
the use of knockout mice as cardiac graft donors would be an effective approach for 
determining the contributions of IL-6 signaling to graft cells.  For these experiments, 
mice deficient in at least four components of IL-6 signaling machinery, IL-6, IL-6 
receptor α, the IL-6 coreceptor gp-130, and the intracellular STAT3 protein could be 
utilized (Figure 21).  Each of these may provide insights into the role of IL-6 signaling 
within the graft.  The outcome of transplants utilizing grafts deficient in IL-6 would 
inform whether or not graft-derived IL-6, potentially produced by hypertrophic cardiac 
myocytes (354, 355) or vascular endothelial cells (356), significantly contributes to CR.  
If graft-derived IL-6 plays an important role in CR, it would be expected that grafts 
deficient in the production of IL-6 will be protected from manifestations of CR, including 




significant amounts of IL-6 that contribute to graft pathology, it is likely that graft cell 
responses to IL-6 are critically involved in CR as well.   
To assess the importance of graft cell responses to IL-6, transplants utilizing 
grafts deficient in the IL-6 receptor α, the IL-6 specific element of the IL-6 receptor 
complex, could be used.  The advantage of using IL-6 receptor α knockouts is that 
specific interruption of IL-6 signaling would occur in graft cells.  However, the limitation 
of IL-6 receptor α knockout grafts is that grafts would still be able to receive signals 
through trans IL-6 signaling by IL-6 bound to the soluble IL-6 receptor α.  If IL-6 
receptor α knockout grafts were protected from CR, it would clearly implicate a role for 
cis IL-6 signaling to graft cells.  While if the grafts were not protected it would indicate 
that cis IL-6 signaling to graft cells was indispensible.  To determine the effects of trans 
IL-6 signaling on the graft, grafts deficient in the IL-6 coreceptor gp-130 or STAT3 could 
be utilized.  In either case, the ability of graft cells to respond to cis or trans IL-6 
signaling would be compromised, suggesting a role for graft responses to IL-6 signaling.  
However, the caveat emptor of interpreting experiments with these mice is that graft cell 
responses to all IL-6 family member cytokines (357, 358) would be abrogated.  Hence, if 
deficiency in gp-130 or STAT3 is protective to the graft, protective effects could not be 
directly ascribed to diminution of IL-6 signals to graft cells, though it would be 
informative when interpreted alongside results with IL-6 receptor α knockout results.   
In addition to elucidating the role of IL-6 signaling in the initiation and 
progression of CAV and interstitial fibrosis associated with CR, these studies would 




Indeed, the signals differentiating pathologic hypertrophy from physiologic hypertrophy 
are not fully understood (351) and likely involves cells other than myocytes (352).  The 
studies presented here suggest that IL-6 may the initiator of pathologic hypertrophy now 
associated with CR of cardiac grafts.  The proposed studies in which the graft is deficient 
in ―sensing‖ this signal would determine if IL-6 is indeed the initiating factor for 
pathologic hypertrophy in CR.   
CTGF Future Studies 
 These experiments suggest that CTGF functions as a downstream mediator of 
fibrosis in CR of cardiac grafts.  Though CTGF neutralization was effective in reducing 
the deposition of fibrotic tissue, interstitial fibrosis still occurred.  Though there may be 
multiple reasons for the incomplete inhibition of fibrosis with anti-CTGF mAb, attempts 
at optimizing the neutralization protocol might clarify the promise of CTGF 
neutralization as a fibrosis reducing therapy.  In these studies, CTGF neutralization began 
on day 7 post transplant.  This time was chosen for two reasons.  First, preliminary data 
suggested that CTGF was upregulated as early as day 7 post transplant.  Second, we were 
concerned that perioperative administration of anti-CTGF mAb may interfere with the 
healing process associated with surgery.  However, early postoperative events might 
influence the evolution of CR.  Hence, it is conceivable that perioperative and continuous 
neutralization of CTGF would provide greater protection against cardiac fibrosis. 
 In addition to its effects on fibrosis, we observed small differences in the 
recruitment of T cells as well as cardiomyocyte hypertrophy.  Though the effect of CTGF 




progression of CAV was not assessed and may be more important.  Investigation of the 
role of CTGF in CAV is of the utmost importance, as CAV is a primary cause of 
transplant recipient death, and also because previous studies implicate CTGF as a key 
factor in adaptive vascular remodeling (258).  Future studies should aim to determine 
whether CTGF neutralization reduces the frequency and/or amount of occlusion in 
cardiac transplants through morphometric analysis of elastin stained sections.  As an 
alternative approach, CTGF neutralization could be attempted in recipients of vessel 
grafts, as the effect of CTGF neutralization could be easily assessed in this setting. 
 In these investigations decreased fibrotic area was not associated with decreased 
type I collagen transcripts.  The accumulation of ECM proteins such as type I collagen is 
the result of two factors—the rate of synthesis and the rate of degradation.  This raises the 
interesting possibility that CTGF neutralization inhibits graft fibrosis by maintaining 
ECM degrading factors rather than preventing upregulation of ECM synthesis.  This 
interesting possibility could be examined by evaluating matrix metalloproteinase (MMP) 
1 and 2 levels and activities through western blot and zymography.  Indeed, suppression 
of ECM degradation via reduction of MMPs has already been observed in other settings 
of ventricular fibrosis (359). 
Concluding Remarks 
 Together, these studies have provided significant insights into our understanding 
of the etiology and mechanisms of CR of cardiac grafts.  First, the evolution of graft 
hypertrophy in response to IL-6 initiated events may provide a non-invasive biomarker 




these investigations suggest that therapeutic approaches targeting IL-6 and CTGF may 
significantly ameliorate CR pathology in cardiac grafts.  Further, CTGF neutralization 
may represent a therapeutic that specifically targets downstream events in CR of cardiac 
grafts without significantly increasing the immunosuppressed condition in which most 
transplant recipients live.  Hopefully basic science discoveries like these will spur clinical 













Appendix 2  Intragraft Expression of Transgenes in Cardiac Allografts Transduced with 
Adenoviral TGFβ (AdTGFβ) or Adenoviral CTGF (AdCTGF). 
 
Appendix 3  Dual Transduction of AdTGFβ and AdCTGF does not produce an Additive Fibrotic 





Appendix 4  Comparison of Graft-reactive Antibody Production in Recipients of Cardiac Allografts 
Transiently Depleted of CD4+ Cells and also receiving control rat IgG or anti-IL-6 antibody therapy.  
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